バイオマーカー市場規模、シェア、動向、2031年までの世界予測

世界のバイオマーカー市場は、2026年の679億5,000万米ドルから2031年には1,121億米ドルに達し、同期間の年平均成長率（CAGR）は10.5%に達するとMarketsandMarketsでは予測しています。この成長は、人工知能（AI）、デジタルパソロジー、バイオインフォマティクスの統合が進んでいることや、プレシジョン・メディシン（精密医療）およびコンパニオン診断の導入が拡大していることによって牽引されています。

調査範囲：

本調査レポートは、世界のバイオマーカー市場を、製品・サービス（オファリング）、種類、研究分野、技術、疾患領域、およびエンドユーザー別に分類しています。

本レポートでは、市場の成長に影響を与える主要な要因（促進要因、抑制要因、課題、機会など）に関する包括的な情報を提供します。また、主要な業界プレーヤーの詳細な分析も行い、各社の事業概要、製品・ソリューション、主要戦略、提携・パートナーシップ・契約関係などに関する知見を提供します。さらに、世界のバイオマーカー市場における新規承認や製品発売、最近の提携、買収、その他の動向についても網羅しています。

本レポートを購入するメリット：

本レポートは、バイオマーカー市場全体およびその細分化された市場セグメントにおける収益規模の精度の高い推定値を提供することで、市場のリーダー企業や新規参入企業を支援します。また、ステークホルダーが競争環境を深く理解し、自社の事業をより効果的に位置づけ、適切な市場参入戦略を策定するための知見を得るのにも役立ちます。さらに、市場の動向を把握し、主要な促進要因、抑制要因、機会、課題に関する情報を得ることも可能にします。

本レポートでは、以下の点に関する知見を提供します。

主要な推進要因（プレシジョン・メディシンやコンパニオン診断の採用拡大、NGS・PCR・プロテオミクス・マルチオミクスプラットフォームの利用増加、創薬および臨床試験設計におけるバイオマーカー利用の拡大、がん・心血管疾患・神経疾患・感染症の負担増大、リキッドバイオプシーや低侵襲バイオマーカー検査の普及、AI・デジタルパソロジー・バイオインフォマティクスの統合）、阻害要因（高度なバイオマーカーの探索・検証にかかる高コスト、複雑な規制および償還プロセス）、機会（標的療法や免疫療​​法と連携したバイオマーカーの共同開発、腫瘍学および神経科学分野における血液由来バイオマーカーの拡大、プロテオミクス・空間生物学・マルチオミクスによるバイオマーカー探索の成長、バイオマーカー測定法開発・検証のアウトソーシング拡大）、および課題（探索段階のバイオマーカーを臨床的に検証された検査へと実用化すること、患者の多様性や疾患の複雑性）

• 製品開発・イノベーション：世界のバイオマーカー市場における次世代技術や研究開発活動に関する詳細な知見
• 市場開拓：有望な市場に関する包括的な情報（地域別の市場分析を含む）
• 市場の多角化：世界のバイオマーカー市場における未開拓地域、最近の動向、投資に関する詳細情報
• 競合分析：主要企業の市場シェア、成長戦略、製品ポートフォリオに関する詳細な評価。主要な業界プレーヤーについて、戦略、製品の発売・承認、買収、提携、合意、共同開発、その他の最近の動向、投資・資金調達活動、ブランド・製品の比較分析、ベンダー評価および財務指標などを詳細に分析しています。

Report Description

The global biomarkers market is expected to reach USD 112.10 billion by 2031 from USD 67.95 billion in 2026, at a CAGR of 10.5% from 2026 to 2031. This growth is driven by the increasing integration of artificial intelligence, digital pathology, and bioinformatics, as well as the rising adoption of precision medicine and companion diagnostics.

In 2025, the predictive biomarkers segment accounted for the largest share of the efficacy biomarkers market.

The biomarkers market is categorized by type into three segments: safety, efficacy, and validation biomarkers. The efficacy biomarkers segment is further divided into predictive, surrogate, pharmacodynamic, and prognostic biomarkers. In 2024, predictive biomarkers accounted for the largest share globally in the efficacy biomarkers segment. This dominance is primarily due to their crucial role in facilitating personalized treatment by identifying patients most likely to respond to specific therapies. This capability ultimately improves treatment outcomes and enhances clinical decision-making.

The use of predictive biomarkers has gained significant traction in fields such as oncology, autoimmune diseases, and infectious diseases. Additionally, the increasing number of companion diagnostic approvals for predictive biomarkers is driving market adoption. For instance, in June 2026, the FDA approved Roche’s first companion diagnostic to assess the PTEN protein in prostate cancer. The VENTANA PTEN assay enables the identification of patients eligible for more targeted treatment decisions.

By technology, the immunoassays segment held the largest share of the biomarkers market in 2025.

The biomarkers market is divided into several technologies, including immunoassays, NGS (next-generation sequencing), PCR (polymerase chain reaction), mass spectrometry, chromatography, and others. In 2025, immunoassays are expected to hold the largest share of the biomarker market due to their high specificity and ability to detect a wide range of biomarkers across various disease areas, particularly in oncology, cardiology, and infectious diseases.

Immunoassays are favored for biomarker detection because they are compatible with both clinical diagnostics and research applications. Additionally, their scalability and automation capabilities enable high-throughput testing, which is essential for meeting the increasing demand for precision diagnostics.

Major companies are actively enhancing their immunoassay platforms to improve their diagnostic offerings. For instance, Roche provides the Elecsys Anti-p53 immunoassay for cancer diagnostics, while Abbott is expanding its ARCHITECT and Alinity immunoassay systems to test for infectious diseases and monitor chronic conditions.

APAC is the fastest-growing regional segment in the global biomarkers market from 2026 to 2031.

The biomarkers market is divided into several regions: North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. The Asia Pacific region is expected to experience the highest CAGR during the forecast period. This growth is primarily driven by the expanding healthcare infrastructure in countries such as China, India, and Japan, along with increasing investments in precision medicine, genomic research, and diagnostic innovation.

The rising prevalence of chronic diseases, including cancer, cardiovascular disorders, metabolic diseases, and infectious diseases, is accelerating the demand for biomarker-based diagnostics and personalized treatment approaches. Additionally, the growth of clinical trial activities, the increasing adoption of companion diagnostics, supportive government initiatives for biotechnology and life sciences research, and the rapid integration of genomics, proteomics, and AI-enabled analytics are all contributing to the regional market growth.

Furthermore, expanding local biopharmaceutical manufacturing capabilities and improving regulatory frameworks are enhancing commercialization opportunities, establishing the Asia Pacific region as a significant hub for growth and innovation in the biomarkers market.

The primary interviews conducted for this report can be categorized as follows:

• By Respondent: Supply Side (70%) and Demand Side (30%)
• By Designation: Managers (45%), CXO and Directors (30%), and Executives (25%)
• By Region: North America (40%), Europe (25%), the Asia Pacific (25%), Latin America (5%), and the Middle East & Africa (5%)

List of Companies Profiled in the Report

• Hoffmann-La Roche Ltd. (Switzerland)
• Merck KGaA (Germany)
• Abbott (US)
• Thermo Fisher Scientific, Inc. (US)
• QIAGEN (Germany)
• Charles River Laboratories (US)
• Eurofins Scientific (Luxembourg)
• LabCorp (US)
• Revvity (US)
• bioMérieux (France)
• Guardant Health (US)
• JSR Corporation (Crown Biosciences) (Japan)
• Agilent Technologies, Inc. (US)
• Bio-Rad Laboratories (US)
• Illumina, Inc. (US)
• Quanterix (US)
• Meso Scale Diagnostics, LLC (US)
• Intertek Group Plc (UK)
• Meridian Bioscience (US)
• BioAgilytix Labs (US)
• R-Biopharm AG (Germany)
• Enzo Biochem (US)
• WuXi AppTec (China)
• Standard BioTools (US)
• Diatech Pharmacogenetics (Italy)
• Synexa Life Sciences BV (Netherlands)
• Proteome Sciences (UK)
• Pillar Biosciences (US)
• StressMarq Biosciences Inc. (Canada)
• Sebia (France)
• Bio-Techne (US)
• C2N Diagnostics (US)
• NorthEast Bioanalytical Laboratories (US)
• Signosis (US)
• Myriad Genetics, Inc. (US)

Research Coverage:

This research report categorizes the global biomarkers market by offering, type, research area, technology, disease indication, and end user.

The report provides comprehensive information about the key factors influencing the growth of the biomarkers market, including drivers, restraints, challenges, and opportunities. It also includes a detailed analysis of major industry players, offering insights into their business overviews, products, solutions, key strategies, collaborations, partnerships, and agreements. Additionally, the report covers new approvals and product launches, as well as recent collaborations, acquisitions, and developments within the global biomarkers market.

Key Benefits of Buying the Report:

The report will help market leaders and new entrants by providing the closest approximations of revenue numbers for the overall biomarkers market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain insights to position their businesses more effectively and develop suitable go-to-market strategies. This report will enable stakeholders to understand the market’s pulse and provide information on the key drivers, restraints, opportunities, and challenges.

The report provides insights into the following pointers:

• Analysis of key drivers (rising adoption of precision medicine and companion diagnostics, growing use of NGS, PCR, proteomics, and multi-omics platforms, increasing biomarker use in drug discovery and clinical trial design, rising burden of cancer, cardiovascular, neurological, and infectious diseases, expansion of liquid biopsy and minimally invasive biomarker testing, and increasing integration of AI, digital pathology, and bioinformatics), restraints (high cost of advanced biomarker discovery and validation and complex regulatory and reimbursement pathways), opportunities (co-development of biomarkers with targeted therapies and immunotherapies, expansion of blood-based biomarkers for oncology and neurology, growth in proteomics, spatial biology, and multi-omics biomarker discovery, and rising outsourcing of biomarker assay development and validation), and challenges (translating discovery biomarkers into clinically validated tests and patient heterogeneity and disease complexity)
• Product Development/Innovation: Detailed insights on upcoming technologies and research & development activities in the global biomarkers market
• Market Development: Comprehensive information about lucrative markets; the report analyzes the market across varied regions.
• Market Diversification: Exhaustive information about untapped geographies, recent developments, and investments in the global biomarkers market
• Competitive Assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players. A detailed analysis of the key industry players has been conducted to provide insights into their strategies, product launches/approvals, acquisitions, partnerships, agreements, collaborations, other recent developments, investment and funding activities, brand/product comparative analysis, and vendor valuation and financial metrics for the global biomarkers market.

Table of Contents

1 INTRODUCTION 56
1.1 STUDY OBJECTIVES 56
1.2 MARKET DEFINITION 56
1.3 STUDY SCOPE 56
1.3.1 MARKET SEGMENTATION & REGIONAL SCOPE 57
1.3.2 INCLUSIONS & EXCLUSIONS 58
1.3.3 YEARS CONSIDERED 59
1.4 CURRENCY CONSIDERED 59
1.5 STAKEHOLDERS 59
1.6 SUMMARY OF CHANGES 60
2 EXECUTIVE SUMMARY 61
2.1 KEY INSIGHTS & MARKET HIGHLIGHTS 61
2.2 KEY MARKET PARTICIPANTS: INSIGHTS & STRATEGIC DEVELOPMENTS 63
2.3 DISRUPTIVE TRENDS SHAPING MARKET GROWTH 64
2.4 HIGH-GROWTH SEGMENTS & EMERGING FRONTIERS 65
2.5 SNAPSHOT: GLOBAL MARKET SIZE, GROWTH RATE, AND FORECAST 66
3 PREMIUM INSIGHTS 67
3.1 BIOMARKERS MARKET OVERVIEW 67
3.2 BIOMARKERS MARKET, BY TYPE & REGION 68
3.3 BIOMARKERS MARKET: GEOGRAPHIC SNAPSHOT 70
4 MARKET OVERVIEW 71
4.1 INTRODUCTION 71
4.2 MARKET DYNAMICS 71
4.2.1 DRIVERS 73
4.2.1.1 Rising adoption of precision medicine and companion diagnostics 73
4.2.1.2 Growing use of NGS, PCR, proteomics, and multi-omics platforms 73
4.2.1.3 Increasing biomarker use in drug discovery and clinical trial design 73
4.2.1.4 Rising burden of cancer, cardiovascular, neurological, and infectious diseases 74
4.2.1.5 Expansion of liquid biopsy and minimally invasive biomarker testing 74
4.2.1.6 Increasing integration of AI, digital pathology, and bioinformatics 74
4.2.2 RESTRAINTS 75
4.2.2.1 High cost of advanced biomarker discovery and validation 75
4.2.2.2 Complex regulatory and reimbursement pathways 75
4.2.3 OPPORTUNITIES 75
4.2.3.1 Co-development of biomarkers with targeted therapies and immunotherapies 75
4.2.3.2 Expansion of blood-based biomarkers for oncology and neurology 75
4.2.3.3 Growth in proteomics, spatial biology, and multi-omics biomarker discovery 76
4.2.3.4 Rising outsourcing of biomarker assay development and validation 76
4.2.4 CHALLENGES 76
4.2.4.1 Patient heterogeneity and disease complexity 76
4.2.4.2 Translating discovery biomarkers into clinically validated tests 77
4.3 UNMET NEEDS & WHITE SPACES 77
4.4 INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES 78
4.5 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS 79
5 INDUSTRY TRENDS 80
5.1 PORTER’S FIVE FORCES ANALYSIS 80
5.1.1 THREAT OF NEW ENTRANTS 81
5.1.2 THREAT OF SUBSTITUTES 81
5.1.3 BARGAINING POWER OF BUYERS 81
5.1.4 BARGAINING POWER OF SUPPLIERS 81
5.1.5 INTENSITY OF COMPETITIVE RIVALRY 81
5.2 MACROECONOMIC OUTLOOK 82
5.2.1 INTRODUCTION 82
5.2.2 GDP TRENDS & FORECAST 82
5.2.3 TRENDS IN GLOBAL BIOMARKERS MARKET 83
5.3 SUPPLY CHAIN ANALYSIS 83
5.4 VALUE CHAIN ANALYSIS 84
5.5 ECOSYSTEM ANALYSIS 86
5.6 PRICING ANALYSIS 87
5.6.1 AVERAGE SELLING PRICE TREND OF ASSAY KITS, BY KEY PLAYER,
2023–2025 87
5.6.2 INDICATIVE SELLING PRICE OF CONSUMABLES, BY REGION, 2025 89
5.7 TRADE ANALYSIS 90
5.7.1 IMPORT DATA 90
5.7.2 EXPORT DATA 91
5.7.3 IMPORT VOLUME 92
5.7.4 EXPORT VOLUME 92
5.8 KEY CONFERENCES & EVENTS, 2026–2027 93
5.9 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 94
5.10 INVESTMENT/FUNDING ACTIVITY 94
5.11 CASE STUDY ANALYSIS 95
5.12 IMPACT OF 2025 US TARIFFS ON BIOMARKERS MARKET 97
5.12.1 INTRODUCTION 97
5.12.2 KEY TARIFF RATES 97
5.12.3 PRICE IMPACT ANALYSIS 98
5.12.4 IMPACT ON COUNTRY/REGION 98
5.12.4.1 North America 98
5.12.4.2 Europe 99
5.12.4.3 Asia Pacific 99
5.12.5 IMPACT ON END-USE INDUSTRIES 100
5.12.5.1 Pharmaceutical & biotechnology companies 100
5.12.5.2 Hospitals & diagnostic laboratories 100
5.12.5.3 Academic & research institutes 101
5.12.5.4 Other end users 101
6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS 102
6.1 TECHNOLOGY ANALYSIS 102
6.1.1 KEY TECHNOLOGIES 102
6.1.1.1 Immunoassays 102
6.1.1.2 Next-generation sequencing (NGS) 102
6.1.1.3 Polymerase chain reaction (PCR) 102
6.1.1.4 In situ hybridization 103
6.1.1.5 Microarrays 103
6.1.1.6 Mass spectrometry 103
6.1.2 ADJACENT TECHNOLOGIES 104
6.1.2.1 Artificial intelligence (AI) and machine learning (ML) 104
6.1.2.2 Sensors (wearable devices) 104
6.1.3 COMPLEMENTARY TECHNOLOGIES 104
6.1.3.1 Liquid biopsy 104
6.1.3.2 CRISPR 104
6.2 TECHNOLOGY/PRODUCT ROADMAP 105
6.3 PATENT ANALYSIS 105
6.3.1 TOP APPLICANTS/OWNERS (COMPANIES) FOR BIOMARKER PATENTS,
2015–2025 106
6.4 FUTURE APPLICATIONS 107
6.5 IMPACT OF AI/GEN AI ON BIOMARKERS MARKET 108
6.5.1 TOP USE CASES & MARKET POTENTIAL 109
6.5.2 CASE STUDIES OF AI IMPLEMENTATION IN BIOMARKERS MARKET 110
6.5.3 INTERCONNECTED ADJACENT ECOSYSTEMS & IMPACT ON MARKET PLAYERS 110
6.5.4 CLIENTS’ READINESS TO ADOPT GENERATIVE AI IN BIOMARKERS MARKET 111
6.6 SUCCESS STORIES & REAL-WORLD APPLICATIONS 112
7 SUSTAINABILITY & REGULATORY LANDSCAPE 113
7.1 REGIONAL REGULATIONS & COMPLIANCE 113
7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 113
7.1.2 REGULATORY FRAMEWORK 120
7.1.3 INDUSTRY STANDARDS 122
7.2 SUSTAINABILITY IMPACT & REGULATORY POLICY INITIATIVES 123
7.3 CERTIFICATIONS, LABELING, AND ECO-STANDARDS 123
8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR 125
8.1 DECISION-MAKING PROCESS 125
8.2 BUYER STAKEHOLDERS & BUYING EVALUATION CRITERIA 126
8.2.1 KEY STAKEHOLDERS IN BUYING PROCESS 126
8.2.2 KEY BUYING CRITERIA, BY END USER 127
8.3 ADOPTION BARRIERS & INTERNAL CHALLENGES 128
8.4 UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES 128
8.5 MARKET PROFITABILITY 129
9 BIOMARKERS MARKET, BY OFFERING 130
9.1 INTRODUCTION 131
9.2 CONSUMABLES 131
9.2.1 ASSAY KITS 135
9.2.1.1 Growing demand for assay kits in biomarker detection, quantification, and characterization to support growth 135
9.2.2 REAGENTS & CHEMICALS 139
9.2.2.1 Recurrent usage of reagents & chemicals in drug discovery and development to support demand 139
9.2.3 OTHER CONSUMABLES 143
9.3 SERVICES 147
9.3.1 GRADUAL TRANSITION FROM IN-HOUSE BIOMARKER TESTING TO OUTSOURCING SERVICES TO FUEL MARKET EXPANSION 147
9.4 SOFTWARE 152
9.4.1 INCREASING ADOPTION OF BIOINFORMATICS TOOLS TO
DRIVE MARKET GROWTH 152
10 BIOMARKERS MARKET, BY TYPE 156
10.1 INTRODUCTION 157
10.2 SAFETY BIOMARKERS 157
10.2.1 WIDE APPLICATIONS OF SAFETY BIOMARKERS IN THERAPEUTIC AREAS & DEVELOPMENT TO BOOST MARKET GROWTH 157
10.3 EFFICACY BIOMARKERS 161
10.3.1 PREDICTIVE BIOMARKERS 165
10.3.1.1 Rising applications of biomarkers in personalized medicine to drive market 165
10.3.2 SURROGATE BIOMARKERS 169
10.3.2.1 Ability to serve as reliable indicators in place of clinical endpoints to support market growth 169
10.3.3 PHARMACODYNAMIC BIOMARKERS 173
10.3.3.1 Increasing utilization of pharmacodynamic biomarkers in biomarker and drug development to boost market 173
10.3.4 PROGNOSTIC BIOMARKERS 177
10.3.4.1 Increasing number of clinical trials to support growth of prognostic biomarkers 177
10.4 VALIDATION BIOMARKERS 181
10.4.1 RISING RESEARCH FOR NEW DRUG DISCOVERY & DEVELOPMENT TO BOOST MARKET GROWTH 181
11 BIOMARKERS MARKET, BY RESEARCH AREA 185
11.1 INTRODUCTION 186
11.2 GENOMICS 187
11.2.1 ADVANCEMENTS IN GENOMICS TECHNOLOGIES TO DRIVE SEGMENT GROWTH 187
11.3 PROTEOMICS 191
11.3.1 GROWING PATIENT POPULATION WITH CHRONIC DISEASES TO DRIVE DEMAND 191
11.4 METABOLOMICS 195
11.4.1 RISING INCIDENCE OF DIABETES AND OBESITY-RELATED CONDITIONS TO SUPPORT MARKET GROWTH 195
11.5 OTHER RESEARCH AREAS 198
12 BIOMARKERS MARKET, BY TECHNOLOGY 203
12.1 INTRODUCTION 204
12.2 IMMUNOASSAYS 204
12.2.1 ELISA 209
12.2.1.1 Extensive application of ELISA assays in clinical laboratories to support growth 209
12.2.2 PROTEIN MICROARRAYS 213
12.2.2.1 Quick and cost-effective nature of technology to support growth 213
12.2.3 WESTERN BLOT 216
12.2.3.1 Increasing investments in proteomics research to drive market 216
12.3 NEXT-GENERATION SEQUENCING (NGS) 220
12.3.1 TECHNOLOGICAL ADVANCEMENTS IN NGS PLATFORMS TO SUPPORT GROWTH 220
12.4 POLYMERASE CHAIN REACTION (PCR) 224
12.4.1 RAPID AND SENSITIVE DETECTION OF GENETIC BIOMARKERS TO DRIVE MARKET 224
12.5 MASS SPECTROMETRY 228
12.5.1 INTEGRATION WITH OMICS TECHNOLOGIES TO DRIVE GROWTH 228
12.6 CHROMATOGRAPHY 232
12.6.1 GROWING UTILIZATION IN PROTEOMICS RESEARCH TO SUPPORT MARKET GROWTH 232
12.7 OTHER TECHNOLOGIES 235
13 BIOMARKERS MARKET, BY APPLICATION 240
13.1 INTRODUCTION 241
13.2 CLINICAL DIAGNOSTICS 241
13.2.1 GROWING FOCUS ON EARLY DISEASE DETECTION AND DIAGNOSIS TO SUPPORT DEMAND 241
13.3 DRUG DISCOVERY & DEVELOPMENT 245
13.3.1 INCREASING UTILIZATION OF BIOMARKERS IN DRUG DEVELOPMENT TO SUPPORT GROWTH 245
13.4 PERSONALIZED MEDICINE 250
13.4.1 GROWING PREFERENCE FOR PRECISION THERAPEUTICS TO SUPPORT DEMAND 250
13.5 CLINICAL RESEARCH 254
13.5.1 GROWING NUMBER OF CLINICAL TRIALS TO PROPEL MARKET 254
13.6 OTHER APPLICATIONS 257
14 BIOMARKERS MARKET, BY DISEASE INDICATION 262
14.1 INTRODUCTION 263
14.2 CANCER 263
14.2.1 BREAST CANCER 269
14.2.1.1 Expanding precision oncology and companion diagnostics to drive global growth in breast cancer biomarkers 269
14.2.2 LUNG CANCER 272
14.2.2.1 Expanding targeted therapies and rapid molecular profiling to drive global growth in lung cancer biomarkers 272
14.2.3 COLORECTAL CANCER 276
14.2.3.1 Expanding RAS/BRAF testing, liquid biopsy, and biomarker-linked targeted therapies to drive global 276
14.2.4 PROSTATE CANCER 279
14.2.4.1 Growth in HRR, PTEN, and liquid biopsy testing to accelerate biomarker adoption 279
14.2.5 HEMATOLOGICAL CANCER 283
14.2.5.1 Rising MRD monitoring and targeted hematology therapies to drive global growth in hematological cancer biomarkers 283
14.2.6 OTHER CANCERS 286
14.3 INFECTIOUS DISEASES 290
14.3.1 HIV/AIDS 294
14.3.1.1 Expanding self-testing and viral load monitoring to drive global growth 294
14.3.2 HEPATITIS (B & C) 298
14.3.2.1 Rising hepatitis screening and automated immunoassay adoption to drive growth of HBV and HCV biomarkers 298
14.3.3 RESPIRATORY INFECTIONS 301
14.3.3.1 Rising MRD monitoring and targeted hematology therapies to drive global growth in hematological cancer biomarkers 301
14.3.4 OTHER INFECTIOUS DISEASES 305
14.4 IMMUNOLOGICAL DISORDERS 308
14.4.1 RHEUMATOID ARTHRITIS 313
14.4.1.1 Earlier diagnosis and therapy-response stratification to drive growth in rheumatoid arthritis biomarkers 313
14.4.2 INFLAMMATORY BOWEL DISEASE 316
14.4.2.1 Non-invasive inflammation monitoring and targeted therapy management to drive growth in IBD biomarkers 316
14.4.3 OTHER IMMUNOLOGICAL DISORDERS 320
14.5 NEUROLOGICAL DISORDERS 323
14.5.1 ALZHEIMER’S DISEASE 328
14.5.1.1 Growing demand for less-invasive alternatives to PET imaging and cerebrospinal fluid testing to boost market growth 328
14.5.2 PARKINSON’S DISEASE 331
14.5.2.1 Alpha-synuclein and digital biomarker advances to drive growth in Parkinson’s disease biomarkers 331
14.5.3 MULTIPLE SCLEROSIS 335
14.5.3.1 Blood-based neurofilament light chain testing to strengthen growth in multiple sclerosis biomarkers 335
14.5.4 OTHER NEUROLOGICAL DISORDERS 338
14.6 METABOLIC & ENDOCRINE DISORDERS 341
14.6.1 DIABETES 345
14.6.1.1 Continuous glucose-ketone monitoring and connected diabetes care to drive growth in diabetes biomarkers 345
14.6.2 OBESITY 349
14.6.2.1 GLP-1 therapy expansion and payer demand for response prediction to drive growth in obesity biomarkers 349
14.6.3 OTHER METABOLIC & ENDOCRINE DISORDERS 352
14.7 CARDIOVASCULAR DISORDERS 356
14.7.1 CONTINUOUS INNOVATION IN CARDIAC BIOMARKERS TO BOOST MARKET GROWTH 356
14.8 OTHER DISEASE INDICATIONS 360
15 BIOMARKERS MARKET, BY END USER 364
15.1 INTRODUCTION 365
15.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 365
15.2.1 GROWING MARKET STRATEGIES BY KEY PLAYERS TO SUPPORT MARKET GROWTH 365
15.3 HOSPITALS & DIAGNOSTIC LABORATORIES 369
15.3.1 VITAL ROLE OF BIOMARKERS AS BIOLOGICAL INDICATORS IN DIAGNOSIS OF DISEASES TO FUEL MARKET GROWTH 369
15.4 ACADEMIC & RESEARCH INSTITUTES 373
15.4.1 INCREASING FUNDING ACTIVITIES TO DRIVE MARKET 373
15.5 OTHER END USERS 376
16 BIOMARKERS MARKET, BY REGION 381
16.1 INTRODUCTION 382
16.2 NORTH AMERICA 382
16.2.1 US 391
16.2.1.1 Rising focus on biopharma research to support growth 391
16.2.2 CANADA 398
16.2.2.1 Increasing incidence of cancer to drive biomarkers market growth 398
16.3 EUROPE 405
16.3.1 GERMANY 414
16.3.1.1 Growth in biopharmaceutical R&D activities to propel growth 414
16.3.2 UK 422
16.3.2.1 Government funding and strategic collaborations with biotech firms to boost adoption of biomarkers 422
16.3.3 FRANCE 429
16.3.3.1 Increasing government investment for proteomics & genomics research to drive growth 429
16.3.4 ITALY 436
16.3.4.1 Increasing developments in life science research to fuel growth 436
16.3.5 SPAIN 443
16.3.5.1 R&D initiatives for personalized medicine to support market growth 443
16.3.6 REST OF EUROPE 450
16.4 ASIA PACIFIC 458
16.4.1 CHINA 468
16.4.1.1 Rising incidence of CVD to propel market 468
16.4.2 JAPAN 474
16.4.2.1 Strong regulatory guidelines for drug discovery & development to support market growth 474
16.4.3 INDIA 481
16.4.3.1 Favorable scenario for FDI and increasing number of clinical trials to propel market 481
16.4.4 SOUTH KOREA 489
16.4.4.1 Increasing innovations in NGS technologies to support market growth 489
16.4.5 AUSTRALIA 495
16.4.5.1 Increasing demand for diagnostic solutions to propel market 495
16.4.6 REST OF ASIA PACIFIC 502
16.5 LATIN AMERICA 509
16.5.1 BRAZIL 517
16.5.1.1 Increased government investments in pharmaceutical R&D to drive market 517
16.5.2 MEXICO 524
16.5.2.1 Rising demand for chronic disease treatment to support market growth 524
16.5.3 REST OF LATIN AMERICA 531
16.6 MIDDLE EAST 538
16.6.1 GCC COUNTRIES 545
16.6.1.1 Saudi Arabia 553
16.6.1.1.1 Growing healthcare expenditure to boost market growth 553
16.6.1.2 UAE 560
16.6.1.2.1 Increasing collaborative efforts for pharmaceutical R&D to drive growth 560
16.6.1.3 Rest of GCC countries 567
16.6.2 REST OF MIDDLE EAST 574
16.7 AFRICA 581
16.7.1 INCREASING DEMAND FOR DRUG DISCOVERY & DEVELOPMENT TO PROPEL MARKET 581
17 COMPETITIVE LANDSCAPE 589
17.1 OVERVIEW 589
17.2 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN BIOMARKERS MARKET, 2023−2026 589
17.3 REVENUE ANALYSIS, 2023–2025 590
17.4 MARKET SHARE ANALYSIS, 2025 591
17.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025 594
17.5.1 STARS 594
17.5.2 EMERGING LEADERS 594
17.5.3 PERVASIVE PLAYERS 594
17.5.4 PARTICIPANTS 594
17.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025 596
17.5.5.1 Company footprint 596
17.5.5.2 Region footprint 597
17.5.5.3 Offering footprint 598
17.5.5.4 Technology footprint 599
17.5.5.5 Application footprint 601
17.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025 602
17.6.1 PROGRESSIVE COMPANIES 602
17.6.2 RESPONSIVE COMPANIES 602
17.6.3 DYNAMIC COMPANIES 602
17.6.4 STARTING BLOCKS 602
17.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2025 604
17.6.5.1 Detailed list of key startups/SME players 604
17.6.5.2 Competitive benchmarking of key startups/SME players 605
17.7 COMPANY VALUATION & FINANCIAL METRICS 606
17.7.1 FINANCIAL METRICS 606
17.7.2 COMPANY VALUATION 606
17.8 BRAND/PRODUCT COMPARISON 607
17.9 COMPETITIVE SCENARIO 608
17.9.1 PRODUCT LAUNCHES & APPROVALS 608
17.9.2 DEALS 609
17.9.3 EXPANSIONS 610
18 COMPANY PROFILES 611
18.1 KEY PLAYERS 611
18.1.1 F. HOFFMANN-LA ROCHE LTD. 611
18.1.1.1 Business overview 611
18.1.1.2 Products & services offered 612
18.1.1.3 Recent developments 615
18.1.1.3.1 Product launches & approvals 615
18.1.1.3.2 Deals 617
18.1.1.4 MnM view 617
18.1.1.4.1 Right to win 617
18.1.1.4.2 Strategic choices 617
18.1.1.4.3 Weaknesses & competitive threats 618
18.1.2 DANAHER CORPORATION 619
18.1.2.1 Business overview 619
18.1.2.2 Products offered 620
18.1.2.3 MnM view 621
18.1.2.3.1 Right to win 621
18.1.2.3.2 Strategic choices 622
18.1.2.3.3 Weaknesses & competitive threats 622
18.1.3 ILLUMINA, INC. 623
18.1.3.1 Business overview 623
18.1.3.2 Products & services offered 624
18.1.3.3 Recent developments 625
18.1.3.3.1 Product launches & approvals 625
18.1.3.3.2 Deals 625
18.1.3.4 MnM view 625
18.1.3.4.1 Right to win 625
18.1.3.4.2 Strategic choices 626
18.1.3.4.3 Weaknesses & competitive threats 626
18.1.4 MERCK KGAA 627
18.1.4.1 Business overview 627
18.1.4.2 Products & services offered 628
18.1.4.3 Recent developments 632
18.1.4.3.1 Deals 632
18.1.4.3.2 Expansions 633
18.1.4.4 MnM view 633
18.1.4.4.1 Right to win 633
18.1.4.4.2 Strategic choices 633
18.1.4.4.3 Weaknesses & competitive threats 633
18.1.5 THERMO FISHER SCIENTIFIC INC. 634
18.1.5.1 Business overview 634
18.1.5.2 Products & services offered 635
18.1.5.3 Recent developments 641
18.1.5.3.1 Product approvals 641
18.1.5.3.2 Deals 641
18.1.5.3.3 Expansions 643
18.1.5.4 MnM view 643
18.1.5.4.1 Right to win 643
18.1.5.4.2 Strategic choices 643
18.1.5.4.3 Weaknesses & competitive threats 644
18.1.6 QIAGEN 645
18.1.6.1 Business overview 645
18.1.6.2 Products & services offered 646
18.1.6.3 Recent developments 649
18.1.6.3.1 Product launches 649
18.1.6.3.2 Deals 649
18.1.6.3.3 Expansions 650
18.1.7 ABBOTT 651
18.1.7.1 Business overview 651
18.1.7.2 Products & services offered 652
18.1.7.3 Recent developments 654
18.1.7.3.1 Product approvals 654
18.1.7.3.2 Deals 654
18.1.8 AGILENT TECHNOLOGIES, INC. 655
18.1.8.1 Business overview 655
18.1.8.2 Products & services offered 656
18.1.8.3 Recent developments 657
18.1.8.3.1 Product approvals 657
18.1.8.3.2 Deals 659
18.1.9 REVVITY INC. 660
18.1.9.1 Business overview 660
18.1.9.2 Products & services offered 661
18.1.9.3 Recent developments 662
18.1.9.3.1 Product launches 662
18.1.10 CHARLES RIVER LABORATORIES 663
18.1.10.1 Business overview 663
18.1.10.2 Products & services offered 664
18.1.10.3 Recent developments 665
18.1.10.3.1 Deals 665
18.1.11 BIO-RAD LABORATORIES, INC. 666
18.1.11.1 Business overview 666
18.1.11.2 Products & services offered 667
18.1.11.3 Recent developments 668
18.1.11.3.1 Product launches 668
18.1.11.3.2 Deals 669
18.1.12 EUROFINS SCIENTIFIC 670
18.1.12.1 Business overview 670
18.1.12.2 Products & services offered 671
18.1.12.3 Recent developments 672
18.1.12.3.1 Deals 672
18.1.13 BIOMÉRIEUX 673
18.1.13.1 Business overview 673
18.1.13.2 Products & services offered 674
18.1.13.3 Recent developments 675
18.1.13.3.1 Product approvals 675
18.1.13.3.2 Deals 675
18.1.13.3.3 Expansions 676
18.1.14 JSR CORPORATION 677
18.1.14.1 Business overview 677
18.1.14.2 Products & services offered 678
18.1.14.3 Recent developments 679
18.1.14.3.1 Deals 679
18.1.15 GUARDANT HEALTH 680
18.1.15.1 Business overview 680
18.1.15.2 Products & services offered 681
18.1.15.3 Recent developments 682
18.1.15.3.1 Product approvals 682
18.1.15.3.2 Deals 682
18.1.16 LABCORP 685
18.1.16.1 Business overview 685
18.1.16.2 Products & services offered 686
18.1.16.3 Recent developments 687
18.1.16.3.1 Product launches 687
18.1.17 QUANTERIX 688
18.1.17.1 Business overview 688
18.1.17.2 Products & services offered 689
18.1.17.3 Recent developments 690
18.1.17.3.1 Product launches 690
18.1.17.3.2 Deals 690
18.1.18 MESO SCALE DIAGNOSTICS, LLC 691
18.1.18.1 Business overview 691
18.1.18.2 Products & services offered 691
18.1.19 SIEMENS HEALTHINEERS AG 693
18.1.19.1 Business overview 693
18.1.19.2 Products offered 694
18.2 OTHER PLAYERS 696
18.2.1 CELERION 696
18.2.2 STANDARD BIOTOOLS 697
18.2.3 SEBIA 698
18.2.4 BIOAGILYTIX LABS 699
18.2.5 STRESSMARQ BIOSCIENCES INC. 700
18.2.6 NORTHEAST BIOANALYTICAL LABORATORIES LLC 701
18.2.7 SIGNOSIS 702
18.2.8 SERIMMUNE 703
18.2.9 THERAINDX LIFESCIENCES PVT. LTD. 703
18.2.10 SYNEXA LIFE SCIENCES BV 704
18.2.11 DIATECH PHARMACOGENETICS 705
18.2.12 PILLAR BIOSCIENCES 706
18.2.13 R-BIOPHARM AG 707
19 RESEARCH METHODOLOGY 708
19.1 RESEARCH DATA 708
19.1.1 SECONDARY DATA 709
19.1.2 PRIMARY DATA 710
19.2 MARKET ESTIMATION METHODOLOGY 711
19.2.1 INSIGHTS OF PRIMARY EXPERTS 714
19.2.2 TOP-DOWN APPROACH 715
19.3 MARKET GROWTH RATE FORECAST 716
19.4 MARKET BREAKDOWN & DATA TRIANGULATION 717
19.5 RESEARCH ASSUMPTIONS 719
19.6 RESEARCH LIMITATIONS 719
19.7 RISK ASSESSMENT 720
20 APPENDIX 721
20.1 DISCUSSION GUIDE 721
20.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 727
20.3 CUSTOMIZATION OPTIONS 729
20.4 RELATED REPORTS 729
20.5 AUTHOR DETAILS 730

LIST OF TABLES

TABLE 1 BIOMARKERS MARKET: IMPACT ANALYSIS 72
TABLE 2 BIOMARKERS MARKET: PORTER’S FIVE FORCES ANALYSIS 80
TABLE 3 BIOMARKERS MARKET: ROLE IN ECOSYSTEM 86
TABLE 4 AVERAGE SELLING PRICE TREND OF ASSAY KITS, BY KEY PLAYER,
2023–2025 (USD) 88
TABLE 5 INDICATIVE SELLING PRICE OF CONSUMABLES, BY REGION, 2025 89
TABLE 6 IMPORT DATA FOR HS CODE 382219, 2022–2025, (USD THOUSAND) 90
TABLE 7 EXPORT DATA HS CODE 382200, 2022–2025, (USD THOUSAND) 91
TABLE 8 IMPORT VOLUME HS CODE 382219, 2022–2025 (TONS) 92
TABLE 9 EXPORT VOLUME HS CODE 382219, 2022–2025 (TONS) 92
TABLE 10 BIOMARKERS MARKET: KEY CONFERENCES & EVENTS, 2026–2027 93
TABLE 11 CASE STUDY 1: ADVANCED GENOMIC PROFILING TO SUPPORT PRECISION ONCOLOGY ADOPTION 95
TABLE 12 CASE STUDY 2: EXPANSION OF LIQUID BIOPSY ACCESS FOR MINIMALLY INVASIVE CANCER BIOMARKER TESTING 96
TABLE 13 CASE STUDY 3: POPULATION PROTEOMICS EXPANSION TO ACCELERATE BIOMARKER DISCOVERY 96
TABLE 14 US-ADJUSTED RECIPROCAL TARIFF RATES 97
TABLE 15 INDICATIVE LIST OF PATENTS IN BIOMARKERS MARKET, 2025 107
TABLE 16 CASE STUDIES OF AI IMPLEMENTATION IN BIOMARKERS MARKET 110
TABLE 17 CLIENTS’ READINESS TO ADOPT GENERATIVE AI IN BIOMARKERS MARKET 111
TABLE 18 KEY SUCCESS STORIES WITH RESPECT TO REAL-WORLD APPLICATIONS IN BIOMARKERS MARKET 112
TABLE 19 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 114
TABLE 20 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 115
TABLE 21 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 117
TABLE 22 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 119
TABLE 23 COUNTRY-WISE REGULATORY SCENARIO FOR BIOMARKER-BASED PRODUCT & SERVICE PROVIDERS 121
TABLE 24 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY OFFERING (%) 126
TABLE 25 KEY BUYING CRITERIA, BY END USER 127
TABLE 26 BIOMARKERS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 131
TABLE 27 BIOMARKER CONSUMABLES MARKET, BY REGION, 2024–2031 (USD MILLION) 132
TABLE 28 NORTH AMERICA: BIOMARKER CONSUMABLES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 132
TABLE 29 EUROPE: BIOMARKER CONSUMABLES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 133
TABLE 30 ASIA PACIFIC: BIOMARKER CONSUMABLES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 133
TABLE 31 LATIN AMERICA: BIOMARKER CONSUMABLES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 133
TABLE 32 MIDDLE EAST: BIOMARKER CONSUMABLES MARKET, BY REGION,
2024–2031 (USD MILLION) 134
TABLE 33 GCC COUNTRIES: BIOMARKER CONSUMABLES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 134
TABLE 34 BIOMARKER CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION) 135
TABLE 35 BIOMARKER ASSAY KITS MARKET, BY REGION, 2024–2031 (USD MILLION) 136
TABLE 36 NORTH AMERICA: BIOMARKER ASSAY KITS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 137
TABLE 37 EUROPE: BIOMARKER ASSAY KITS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 137
TABLE 38 ASIA PACIFIC: BIOMARKER ASSAY KITS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 138
TABLE 39 LATIN AMERICA: BIOMARKER ASSAY KITS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 138
TABLE 40 MIDDLE EAST: BIOMARKER ASSAY KITS MARKET, BY REGION,
2024–2031 (USD MILLION) 139
TABLE 41 GCC COUNTRIES: BIOMARKER ASSAY KITS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 139
TABLE 42 BIOMARKER REAGENTS & CHEMICALS MARKET, BY REGION,
2024–2031 (USD MILLION) 140
TABLE 43 NORTH AMERICA: BIOMARKER REAGENTS & CHEMICALS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 141
TABLE 44 EUROPE: BIOMARKER REAGENTS & CHEMICALS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 141
TABLE 45 ASIA PACIFIC: BIOMARKER REAGENTS & CHEMICALS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 142
TABLE 46 LATIN AMERICA: BIOMARKER REAGENTS & CHEMICALS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 142
TABLE 47 MIDDLE EAST: BIOMARKER REAGENTS & CHEMICALS MARKET, BY REGION,
2024–2031 (USD MILLION) 143
TABLE 48 GCC COUNTRIES: BIOMARKER REAGENTS & CHEMICALS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 143
TABLE 49 OTHER BIOMARKER CONSUMABLES MARKET, BY REGION,
2024–2031 (USD MILLION) 144
TABLE 50 NORTH AMERICA: OTHER BIOMARKER CONSUMABLES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 145
TABLE 51 EUROPE: OTHER BIOMARKER CONSUMABLES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 145
TABLE 52 ASIA PACIFIC: OTHER BIOMARKER CONSUMABLES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 146
TABLE 53 LATIN AMERICA: OTHER BIOMARKER CONSUMABLES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 146
TABLE 54 MIDDLE EAST: OTHER BIOMARKER CONSUMABLES MARKET, BY REGION,
2024–2031 (USD MILLION) 147
TABLE 55 GCC COUNTRIES: OTHER BIOMARKER CONSUMABLES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 147
TABLE 56 BIOMARKER SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION) 149
TABLE 57 NORTH AMERICA: BIOMARKER SERVICES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 149
TABLE 58 EUROPE: BIOMARKER SERVICES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 150
TABLE 59 ASIA PACIFIC: BIOMARKER SERVICES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 150
TABLE 60 LATIN AMERICA: BIOMARKER SERVICES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 151
TABLE 61 MIDDLE EAST: BIOMARKER SERVICES MARKET, BY REGION,
2024–2031 (USD MILLION) 151
TABLE 62 GCC COUNTRIES: BIOMARKER SERVICES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 151
TABLE 63 BIOMARKER SOFTWARE MARKET, BY REGION, 2024–2031 (USD MILLION) 152
TABLE 64 NORTH AMERICA: BIOMARKER SOFTWARE MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 153
TABLE 65 EUROPE: BIOMARKER SOFTWARE MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 153
TABLE 66 ASIA PACIFIC: BIOMARKER SOFTWARE MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 154
TABLE 67 LATIN AMERICA: BIOMARKER SOFTWARE MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 154
TABLE 68 MIDDLE EAST: BIOMARKER SOFTWARE MARKET, BY REGION,
2024–2031 (USD MILLION) 155
TABLE 69 GCC COUNTRIES: BIOMARKER SOFTWARE MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 155
TABLE 70 BIOMARKERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 157
TABLE 71 SAFETY BIOMARKERS MARKET, BY REGION, 2024–2031 (USD MILLION) 158
TABLE 72 NORTH AMERICA: SAFETY BIOMARKERS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 159
TABLE 73 EUROPE: SAFETY BIOMARKERS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 159
TABLE 74 ASIA PACIFIC: SAFETY BIOMARKERS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 160
TABLE 75 LATIN AMERICA: SAFETY BIOMARKERS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 160
TABLE 76 MIDDLE EAST: SAFETY BIOMARKERS MARKET, BY REGION,
2024–2031 (USD MILLION) 161
TABLE 77 GCC COUNTRIES: SAFETY BIOMARKERS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 161
TABLE 78 EFFICACY BIOMARKERS MARKET, BY REGION, 2024–2031 (USD MILLION) 162
TABLE 79 NORTH AMERICA: EFFICACY BIOMARKERS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 162
TABLE 80 EUROPE: EFFICACY BIOMARKERS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 163
TABLE 81 ASIA PACIFIC: EFFICACY BIOMARKERS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 163
TABLE 82 LATIN AMERICA: EFFICACY BIOMARKERS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 164
TABLE 83 MIDDLE EAST: EFFICACY BIOMARKERS MARKET, BY REGION,
2024–2031 (USD MILLION) 164
TABLE 84 GCC COUNTRIES: EFFICACY BIOMARKERS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 164
TABLE 85 EFFICACY BIOMARKERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 165
TABLE 86 PREDICTIVE BIOMARKERS MARKET, BY REGION, 2024–2031 (USD MILLION) 166
TABLE 87 NORTH AMERICA: PREDICTIVE BIOMARKERS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 167
TABLE 88 EUROPE: PREDICTIVE BIOMARKERS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 167
TABLE 89 ASIA PACIFIC: PREDICTIVE BIOMARKERS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 168
TABLE 90 LATIN AMERICA: PREDICTIVE BIOMARKERS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 168
TABLE 91 MIDDLE EAST: PREDICTIVE BIOMARKERS MARKET, BY REGION,
2024–2031 (USD MILLION) 169
TABLE 92 GCC COUNTRIES: PREDICTIVE BIOMARKERS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 169
TABLE 93 SURROGATE BIOMARKERS MARKET, BY REGION, 2024–2031 (USD MILLION) 170
TABLE 94 NORTH AMERICA: SURROGATE BIOMARKERS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 171
TABLE 95 EUROPE: SURROGATE BIOMARKERS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 171
TABLE 96 ASIA PACIFIC: SURROGATE BIOMARKERS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 172
TABLE 97 LATIN AMERICA: SURROGATE BIOMARKERS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 172
TABLE 98 MIDDLE EAST: SURROGATE BIOMARKERS MARKET, BY REGION,
2024–2031 (USD MILLION) 173
TABLE 99 GCC COUNTRIES: SURROGATE BIOMARKERS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 173
TABLE 100 PHARMACODYNAMIC BIOMARKERS MARKET, BY REGION,
2024–2031 (USD MILLION) 174
TABLE 101 NORTH AMERICA: PHARMACODYNAMIC BIOMARKERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 175
TABLE 102 EUROPE: PHARMACODYNAMIC BIOMARKERS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 175
TABLE 103 ASIA PACIFIC: PHARMACODYNAMIC BIOMARKERS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 176
TABLE 104 LATIN AMERICA: PHARMACODYNAMIC BIOMARKERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 176
TABLE 105 MIDDLE EAST: PHARMACODYNAMIC BIOMARKERS MARKET, BY REGION,
2024–2031 (USD MILLION) 177
TABLE 106 GCC COUNTRIES: PHARMACODYNAMIC BIOMARKERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 177
TABLE 107 PROGNOSTIC BIOMARKERS MARKET, BY REGION, 2024–2031 (USD MILLION) 178
TABLE 108 NORTH AMERICA: PROGNOSTIC BIOMARKERS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 179
TABLE 109 EUROPE: PROGNOSTIC BIOMARKERS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 179
TABLE 110 ASIA PACIFIC: PROGNOSTIC BIOMARKERS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 180
TABLE 111 LATIN AMERICA: PROGNOSTIC BIOMARKERS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 180
TABLE 112 MIDDLE EAST: PROGNOSTIC BIOMARKERS MARKET, BY REGION,
2024–2031 (USD MILLION) 181
TABLE 113 GCC COUNTRIES: PROGNOSTIC BIOMARKERS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 181
TABLE 114 VALIDATION BIOMARKERS MARKET, BY REGION, 2024–2031 (USD MILLION) 182
TABLE 115 NORTH AMERICA: VALIDATION BIOMARKERS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 182
TABLE 116 EUROPE: VALIDATION BIOMARKERS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 183
TABLE 117 ASIA PACIFIC: VALIDATION BIOMARKERS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 183
TABLE 118 LATIN AMERICA: VALIDATION BIOMARKERS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 184
TABLE 119 MIDDLE EAST: VALIDATION BIOMARKERS MARKET, BY REGION,
2024–2031 (USD MILLION) 184
TABLE 120 GCC COUNTRIES: VALIDATION BIOMARKERS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 184
TABLE 121 BIOMARKERS MARKET, BY RESEARCH AREA, 2024–2031 (USD MILLION) 186
TABLE 122 BIOMARKERS MARKET FOR GENOMICS, BY REGION, 2024–2031 (USD MILLION) 188
TABLE 123 NORTH AMERICA: BIOMARKERS MARKET FOR GENOMICS, BY COUNTRY,
2024–2031 (USD MILLION) 188
TABLE 124 EUROPE: BIOMARKERS MARKET FOR GENOMICS, BY COUNTRY,
2024–2031 (USD MILLION) 189
TABLE 125 ASIA PACIFIC: BIOMARKERS MARKET FOR GENOMICS, BY COUNTRY,
2024–2031 (USD MILLION) 189
TABLE 126 LATIN AMERICA: BIOMARKERS MARKET FOR GENOMICS, BY COUNTRY,
2024–2031 (USD MILLION) 189
TABLE 127 MIDDLE EAST: BIOMARKERS MARKET FOR GENOMICS, BY REGION,
2024–2031 (USD MILLION) 190
TABLE 128 GCC COUNTRIES: BIOMARKERS MARKET FOR GENOMICS, BY COUNTRY,
2024–2031 (USD MILLION) 190
TABLE 129 BIOMARKERS MARKET FOR PROTEOMICS, BY REGION,
2024–2031 (USD MILLION) 192
TABLE 130 NORTH AMERICA: BIOMARKERS MARKET FOR PROTEOMICS, BY COUNTRY,
2024–2031 (USD MILLION) 192
TABLE 131 EUROPE: BIOMARKERS MARKET FOR PROTEOMICS, BY COUNTRY,
2024–2031 (USD MILLION) 193
TABLE 132 ASIA PACIFIC: BIOMARKERS MARKET FOR PROTEOMICS, BY COUNTRY,
2024–2031 (USD MILLION) 193
TABLE 133 LATIN AMERICA: BIOMARKERS MARKET FOR PROTEOMICS, BY COUNTRY,
2024–2031 (USD MILLION) 194
TABLE 134 MIDDLE EAST: BIOMARKERS MARKET FOR PROTEOMICS, BY REGION,
2024–2031 (USD MILLION) 194
TABLE 135 GCC COUNTRIES: BIOMARKERS MARKET FOR PROTEOMICS, BY COUNTRY,
2024–2031 (USD MILLION) 194
TABLE 136 BIOMARKERS MARKET FOR METABOLOMICS, BY REGION,
2024–2031 (USD MILLION) 196
TABLE 137 NORTH AMERICA: BIOMARKERS MARKET FOR METABOLOMICS, BY COUNTRY, 2024–2031 (USD MILLION) 196
TABLE 138 EUROPE: BIOMARKERS MARKET FOR METABOLOMICS, BY COUNTRY,
2024–2031 (USD MILLION) 197
TABLE 139 ASIA PACIFIC: BIOMARKERS MARKET FOR METABOLOMICS, BY COUNTRY,
2024–2031 (USD MILLION) 197
TABLE 140 LATIN AMERICA: BIOMARKERS MARKET FOR METABOLOMICS, BY COUNTRY, 2024–2031 (USD MILLION) 197
TABLE 141 MIDDLE EAST: BIOMARKERS MARKET FOR METABOLOMICS, BY REGION,
2024–2031 (USD MILLION) 198
TABLE 142 GCC COUNTRIES: BIOMARKERS MARKET FOR METABOLOMICS, BY COUNTRY, 2024–2031 (USD MILLION) 198
TABLE 143 BIOMARKERS MARKET FOR OTHER RESEARCH AREAS, BY REGION,
2024–2031 (USD MILLION) 199
TABLE 144 NORTH AMERICA: BIOMARKERS MARKET FOR OTHER RESEARCH AREAS,
BY COUNTRY, 2024–2031 (USD MILLION) 200
TABLE 145 EUROPE: BIOMARKERS MARKET FOR OTHER RESEARCH AREAS, BY COUNTRY, 2024–2031 (USD MILLION) 200
TABLE 146 ASIA PACIFIC: BIOMARKERS MARKET FOR OTHER RESEARCH AREAS, BY COUNTRY, 2024–2031 (USD MILLION) 201
TABLE 147 LATIN AMERICA: BIOMARKERS MARKET FOR OTHER RESEARCH AREAS,
BY COUNTRY, 2024–2031 (USD MILLION) 201
TABLE 148 MIDDLE EAST: BIOMARKERS MARKET FOR OTHER RESEARCH AREAS, BY REGION, 2024–2031 (USD MILLION) 202
TABLE 149 GCC COUNTRIES: BIOMARKERS MARKET FOR OTHER RESEARCH AREAS,
BY COUNTRY, 2024–2031 (USD MILLION) 202
TABLE 150 BIOMARKERS MARKET, BY TECHNOLOGY, 2024–2031(USD MILLION) 204
TABLE 151 BIOMARKERS MARKET FOR IMMUNOASSAYS, BY REGION,
2024–2031(USD MILLION) 205
TABLE 152 NORTH AMERICA: BIOMARKERS MARKET FOR IMMUNOASSAYS,
BY COUNTRY, 2024–2031(USD MILLION) 206
TABLE 153 EUROPE: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY COUNTRY,
2024–2031(USD MILLION) 206
TABLE 154 ASIA PACIFIC: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY COUNTRY,
2024–2031(USD MILLION) 207
TABLE 155 LATIN AMERICA: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY COUNTRY, 2024–2031(USD MILLION) 207
TABLE 156 MIDDLE EAST: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY REGION,
2024–2031(USD MILLION) 208
TABLE 157 GCC COUNTRIES: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY COUNTRY, 2024–2031(USD MILLION) 208
TABLE 158 BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE, 2024–2031(USD MILLION) 209
TABLE 159 BIOMARKERS MARKET FOR ELISA, BY REGION, 2024–2031(USD MILLION) 210
TABLE 160 NORTH AMERICA: BIOMARKERS MARKET FOR ELISA, BY COUNTRY,
2024–2031(USD MILLION) 210
TABLE 161 EUROPE: BIOMARKERS MARKET FOR ELISA, BY COUNTRY,
2024–2031(USD MILLION) 211
TABLE 162 ASIA PACIFIC: BIOMARKERS MARKET FOR ELISA, BY COUNTRY,
2024–2031(USD MILLION) 211
TABLE 163 LATIN AMERICA: BIOMARKERS MARKET FOR ELISA, BY COUNTRY,
2024–2031(USD MILLION) 212
TABLE 164 MIDDLE EAST: BIOMARKERS MARKET FOR ELISA, BY REGION,
2024–2031(USD MILLION) 212
TABLE 165 GCC COUNTRIES: BIOMARKERS MARKET FOR ELISA, BY COUNTRY,
2024–2031(USD MILLION) 212
TABLE 166 BIOMARKERS MARKET FOR PROTEIN MICROARRAYS, BY REGION,
2024–2031(USD MILLION) 213
TABLE 167 NORTH AMERICA: BIOMARKERS MARKET FOR PROTEIN MICROARRAYS,
BY COUNTRY, 2024–2031(USD MILLION) 214
TABLE 168 EUROPE: BIOMARKERS MARKET FOR PROTEIN MICROARRAYS, BY COUNTRY, 2024–2031(USD MILLION) 214
TABLE 169 ASIA PACIFIC: BIOMARKERS MARKET FOR PROTEIN MICROARRAYS, BY COUNTRY, 2024–2031(USD MILLION) 215
TABLE 170 LATIN AMERICA: BIOMARKERS MARKET FOR PROTEIN MICROARRAYS,
BY COUNTRY, 2024–2031(USD MILLION) 215
TABLE 171 MIDDLE EAST: BIOMARKERS MARKET FOR PROTEIN MICROARRAYS,
BY REGION, 2024–2031(USD MILLION) 216
TABLE 172 GCC COUNTRIES: BIOMARKERS MARKET FOR PROTEIN MICROARRAYS,
BY COUNTRY, 2024–2031(USD MILLION) 216
TABLE 173 BIOMARKERS MARKET FOR WESTERN BLOT, BY REGION,
2024–2031(USD MILLION) 217
TABLE 174 NORTH AMERICA: BIOMARKERS MARKET FOR WESTERN BLOT, BY COUNTRY, 2024–2031(USD MILLION) 217
TABLE 175 EUROPE: BIOMARKERS MARKET FOR WESTERN BLOT, BY COUNTRY,
2024–2031(USD MILLION) 218
TABLE 176 ASIA PACIFIC: BIOMARKERS MARKET FOR WESTERN BLOT, BY COUNTRY,
2024–2031(USD MILLION) 218
TABLE 177 LATIN AMERICA: BIOMARKERS MARKET FOR WESTERN BLOT, BY COUNTRY,
2024–2031(USD MILLION) 218
TABLE 178 MIDDLE EAST: BIOMARKERS MARKET FOR WESTERN BLOT, BY REGION,
2024–2031(USD MILLION) 219
TABLE 179 GCC COUNTRIES: BIOMARKERS MARKET FOR WESTERN BLOT, BY COUNTRY, 2024–2031(USD MILLION) 219
TABLE 180 BIOMARKERS MARKET FOR NEXT-GENERATION SEQUENCING, BY REGION,
2024–2031(USD MILLION) 221
TABLE 181 NORTH AMERICA: BIOMARKERS MARKET FOR NEXT-GENERATION SEQUENCING, BY COUNTRY, 2024–2031(USD MILLION) 221
TABLE 182 EUROPE: BIOMARKERS MARKET FOR NEXT-GENERATION SEQUENCING,
BY COUNTRY, 2024–2031(USD MILLION) 222
TABLE 183 ASIA PACIFIC: BIOMARKERS MARKET FOR NEXT-GENERATION SEQUENCING,
BY COUNTRY, 2024–2031(USD MILLION) 222
TABLE 184 LATIN AMERICA: BIOMARKERS MARKET FOR NEXT-GENERATION SEQUENCING,
BY COUNTRY, 2024–2031(USD MILLION) 223
TABLE 185 MIDDLE EAST: BIOMARKERS MARKET FOR NEXT-GENERATION SEQUENCING,
BY REGION, 2024–2031(USD MILLION) 223
TABLE 186 GCC COUNTRIES: BIOMARKERS MARKET FOR NEXT-GENERATION SEQUENCING, 2024–2031(USD MILLION) 223
TABLE 187 BIOMARKERS MARKET FOR POLYMERASE CHAIN REACTION, BY REGION,
2024–2031(USD MILLION) 225
TABLE 188 NORTH AMERICA: BIOMARKERS MARKET FOR POLYMERASE CHAIN REACTION,
BY COUNTRY, 2024–2031(USD MILLION) 225
TABLE 189 EUROPE: BIOMARKERS MARKET FOR POLYMERASE CHAIN REACTION,
BY COUNTRY, 2024–2031(USD MILLION) 226
TABLE 190 ASIA PACIFIC: BIOMARKERS MARKET FOR POLYMERASE CHAIN REACTION,
BY COUNTRY, 2024–2031(USD MILLION) 226
TABLE 191 LATIN AMERICA: BIOMARKERS MARKET FOR POLYMERASE CHAIN REACTION,
BY COUNTRY, 2024–2031(USD MILLION) 227
TABLE 192 MIDDLE EAST: BIOMARKERS MARKET FOR POLYMERASE CHAIN REACTION,
BY REGION, 2024–2031(USD MILLION) 227
TABLE 193 GCC COUNTRIES: BIOMARKERS MARKET FOR POLYMERASE CHAIN REACTION,
BY COUNTRY, 2024–2031(USD MILLION) 227
TABLE 194 BIOMARKERS MARKET FOR MASS SPECTROMETRY, BY REGION,
2024–2031(USD MILLION) 229
TABLE 195 NORTH AMERICA: BIOMARKERS MARKET FOR MASS SPECTROMETRY,
BY COUNTRY, 2024–2031(USD MILLION) 229
TABLE 196 EUROPE: BIOMARKERS MARKET FOR MASS SPECTROMETRY, BY COUNTRY,
2024–2031(USD MILLION) 230
TABLE 197 ASIA PACIFIC: BIOMARKERS MARKET FOR MASS SPECTROMETRY, BY COUNTRY, 2024–2031(USD MILLION) 230
TABLE 198 LATIN AMERICA: BIOMARKERS MARKET FOR MASS SPECTROMETRY, BY COUNTRY, 2024–2031(USD MILLION) 231
TABLE 199 MIDDLE EAST: BIOMARKERS MARKET FOR MASS SPECTROMETRY, BY REGION, 2024–2031(USD MILLION) 231
TABLE 200 GCC COUNTRIES: BIOMARKERS MARKET FOR MASS SPECTROMETRY,
BY COUNTRY, 2024–2031(USD MILLION) 231
TABLE 201 BIOMARKERS MARKET FOR CHROMATOGRAPHY, BY REGION,
2024–2031(USD MILLION) 232
TABLE 202 NORTH AMERICA: BIOMARKERS MARKET FOR CHROMATOGRAPHY,
BY COUNTRY, 2024–2031(USD MILLION) 233
TABLE 203 EUROPE: BIOMARKERS MARKET FOR CHROMATOGRAPHY, BY COUNTRY,
2024–2031(USD MILLION) 233
TABLE 204 ASIA PACIFIC: BIOMARKERS MARKET FOR CHROMATOGRAPHY, BY COUNTRY, 2024–2031(USD MILLION) 234
TABLE 205 LATIN AMERICA: BIOMARKERS MARKET FOR CHROMATOGRAPHY, BY COUNTRY, 2024–2031(USD MILLION) 234
TABLE 206 MIDDLE EAST: BIOMARKERS MARKET FOR CHROMATOGRAPHY, BY REGION, 2024–2031(USD MILLION) 235
TABLE 207 GCC COUNTRIES: BIOMARKERS MARKET FOR CHROMATOGRAPHY, BY COUNTRY, 2024–2031(USD MILLION) 235
TABLE 208 BIOMARKERS MARKET FOR OTHER TECHNOLOGIES, BY REGION,
2024–2031(USD MILLION) 236
TABLE 209 NORTH AMERICA: BIOMARKERS MARKET FOR OTHER TECHNOLOGIES,
BY COUNTRY, 2024–2031(USD MILLION) 237
TABLE 210 EUROPE: BIOMARKERS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2024–2031(USD MILLION) 237
TABLE 211 ASIA PACIFIC: BIOMARKERS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2024–2031(USD MILLION) 238
TABLE 212 LATIN AMERICA: BIOMARKERS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2024–2031(USD MILLION) 238
TABLE 213 MIDDLE EAST: BIOMARKERS MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2024–2031(USD MILLION) 239
TABLE 214 GCC COUNTRIES: BIOMARKERS MARKET FOR OTHER TECHNOLOGIES,
BY COUNTRY, 2024–2031(USD MILLION) 239
TABLE 215 BIOMARKERS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 241
TABLE 216 BIOMARKERS MARKET FOR CLINICAL DIAGNOSTICS, BY REGION,
2024–2031 (USD MILLION) 242
TABLE 217 NORTH AMERICA: BIOMARKERS MARKET FOR CLINICAL DIAGNOSTICS,
BY COUNTRY, 2024–2031 (USD MILLION) 243
TABLE 218 EUROPE: BIOMARKERS MARKET FOR CLINICAL DIAGNOSTICS, BY COUNTRY, 2024–2031 (USD MILLION) 243
TABLE 219 ASIA PACIFIC: BIOMARKERS MARKET FOR CLINICAL DIAGNOSTICS, BY COUNTRY, 2024–2031 (USD MILLION) 244
TABLE 220 LATIN AMERICA: BIOMARKERS MARKET FOR CLINICAL DIAGNOSTICS,
BY COUNTRY, 2024–2031 (USD MILLION) 244
TABLE 221 MIDDLE EAST: BIOMARKERS MARKET FOR CLINICAL DIAGNOSTICS, BY REGION, 2024–2031 (USD MILLION) 245
TABLE 222 GCC COUNTRIES: BIOMARKERS MARKET FOR CLINICAL DIAGNOSTICS,
BY COUNTRY, 2024–2031 (USD MILLION) 245
TABLE 223 BIOMARKERS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY REGION, 2024–2031 (USD MILLION) 247
TABLE 224 NORTH AMERICA: BIOMARKERS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2024–2031 (USD MILLION) 247
TABLE 225 EUROPE: BIOMARKERS MARKET FOR DRUG DISCOVERY & DEVELOPMENT,
BY COUNTRY, 2024–2031 (USD MILLION) 248
TABLE 226 ASIA PACIFIC: BIOMARKERS MARKET FOR DRUG DISCOVERY & DEVELOPMENT,
BY COUNTRY, 2024–2031 (USD MILLION) 248
TABLE 227 LATIN AMERICA: BIOMARKERS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2024–2031 (USD MILLION) 249
TABLE 228 MIDDLE EAST: BIOMARKERS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY REGION, 2024–2031 (USD MILLION) 249
TABLE 229 GCC COUNTRIES: BIOMARKERS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2024–2031 (USD MILLION) 249
TABLE 230 LIST OF KEY PERSONALIZED MEDICINE AND RELEVANT BIOMARKERS 250
TABLE 231 BIOMARKERS MARKET FOR PERSONALIZED MEDICINE, BY REGION,
2024–2031 (USD MILLION) 251
TABLE 232 NORTH AMERICA: BIOMARKERS MARKET FOR PERSONALIZED MEDICINE,
BY COUNTRY, 2024–2031 (USD MILLION) 251
TABLE 233 EUROPE: BIOMARKERS MARKET FOR PERSONALIZED MEDICINE, BY COUNTRY, 2024–2031 (USD MILLION) 252
TABLE 234 ASIA PACIFIC: BIOMARKERS MARKET FOR PERSONALIZED MEDICINE,
BY COUNTRY, 2024–2031 (USD MILLION) 252
TABLE 235 LATIN AMERICA: BIOMARKERS MARKET FOR PERSONALIZED MEDICINE,
BY COUNTRY, 2024–2031 (USD MILLION) 253
TABLE 236 MIDDLE EAST: BIOMARKERS MARKET FOR PERSONALIZED MEDICINE, BY REGION, 2024–2031 (USD MILLION) 253
TABLE 237 GCC COUNTRIES: BIOMARKERS MARKET FOR PERSONALIZED MEDICINE,
BY COUNTRY, 2024–2031 (USD MILLION) 253
TABLE 238 NUMBER OF REGISTERED AND RECRUITING CLINICAL STUDIES, BY LOCATION 254
TABLE 239 BIOMARKERS MARKET FOR CLINICAL RESEARCH, BY REGION,
2024–2031 (USD MILLION) 255
TABLE 240 NORTH AMERICA: BIOMARKERS MARKET FOR CLINICAL RESEARCH,
BY COUNTRY, 2024–2031 (USD MILLION) 255
TABLE 241 EUROPE: BIOMARKERS MARKET FOR CLINICAL RESEARCH, BY COUNTRY,
2024–2031 (USD MILLION) 256
TABLE 242 ASIA PACIFIC: BIOMARKERS MARKET FOR CLINICAL RESEARCH, BY COUNTRY, 2024–2031 (USD MILLION) 256
TABLE 243 LATIN AMERICA: BIOMARKERS MARKET FOR CLINICAL RESEARCH, BY COUNTRY, 2024–2031 (USD MILLION) 256
TABLE 244 MIDDLE EAST: BIOMARKERS MARKET FOR CLINICAL RESEARCH, BY REGION, 2024–2031 (USD MILLION) 257
TABLE 245 GCC COUNTRIES: BIOMARKERS MARKET FOR CLINICAL RESEARCH, BY COUNTRY, 2024–2031 (USD MILLION) 257
TABLE 246 BIOMARKERS MARKET FOR OTHER APPLICATIONS, BY REGION,
2024–2031 (USD MILLION) 258
TABLE 247 NORTH AMERICA: BIOMARKERS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 259
TABLE 248 EUROPE: BIOMARKERS MARKET FOR OTHER APPLICATIONS, BY COUNTRY,
2024–2031 (USD MILLION) 259
TABLE 249 ASIA PACIFIC: BIOMARKERS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 260
TABLE 250 LATIN AMERICA: BIOMARKERS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 260
TABLE 251 MIDDLE EAST: BIOMARKERS MARKET FOR OTHER APPLICATIONS, BY REGION, 2024–2031 (USD MILLION) 261
TABLE 252 GCC COUNTRIES: BIOMARKERS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 261
TABLE 253 BIOMARKERS MARKET, BY DISEASE INDICATION, 2024–2031 (USD MILLION) 263
TABLE 254 LIST OF FDA-APPROVED BIOMARKERS FOR CANCER, BY TYPE 264
TABLE 255 BIOMARKERS MARKET FOR CANCER, BY TYPE, 2024–2031 (USD MILLION) 265
TABLE 256 BIOMARKERS MARKET FOR CANCER, BY REGION, 2024–2031 (USD MILLION) 266
TABLE 257 NORTH AMERICA: BIOMARKERS MARKET FOR CANCER, BY COUNTRY,
2024–2031 (USD MILLION) 266
TABLE 258 EUROPE: BIOMARKERS MARKET FOR CANCER, BY COUNTRY,
2024–2031 (USD MILLION) 267
TABLE 259 ASIA PACIFIC: BIOMARKERS MARKET FOR CANCER, BY COUNTRY,
2024–2031 (USD MILLION) 267
TABLE 260 LATIN AMERICA: BIOMARKERS MARKET FOR CANCER, BY COUNTRY,
2024–2031 (USD MILLION) 268
TABLE 261 MIDDLE EAST: BIOMARKERS MARKET FOR CANCER, BY REGION,
2024–2031 (USD MILLION) 268
TABLE 262 GCC COUNTRIES: BIOMARKERS MARKET FOR CANCER, BY COUNTRY,
2024–2031 (USD MILLION) 268
TABLE 263 BIOMARKERS MARKET FOR BREAST CANCER, BY REGION,
2024–2031 (USD MILLION) 269
TABLE 264 NORTH AMERICA: BIOMARKERS MARKET FOR BREAST CANCER, BY COUNTRY, 2024–2031 (USD MILLION) 270
TABLE 265 EUROPE: BIOMARKERS MARKET FOR BREAST CANCER, BY COUNTRY,
2024–2031 (USD MILLION) 270
TABLE 266 ASIA PACIFIC: BIOMARKERS MARKET FOR BREAST CANCER, BY COUNTRY,
2024–2031 (USD MILLION) 271
TABLE 267 LATIN AMERICA: BIOMARKERS MARKET FOR BREAST CANCER, BY COUNTRY, 2024–2031 (USD MILLION) 271
TABLE 268 MIDDLE EAST: BIOMARKERS MARKET FOR BREAST CANCER, BY REGION,
2024–2031 (USD MILLION) 272
TABLE 269 GCC COUNTRIES: BIOMARKERS MARKET FOR BREAST CANCER, BY COUNTRY, 2024–2031 (USD MILLION) 272
TABLE 270 BIOMARKERS MARKET FOR LUNG CANCER, BY REGION,
2024–2031 (USD MILLION) 273
TABLE 271 NORTH AMERICA: BIOMARKERS MARKET FOR LUNG CANCER, BY COUNTRY, 2024–2031 (USD MILLION) 273
TABLE 272 EUROPE: BIOMARKERS MARKET FOR LUNG CANCER, BY COUNTRY,
2024–2031 (USD MILLION) 274
TABLE 273 ASIA PACIFIC: BIOMARKERS MARKET FOR LUNG CANCER, BY COUNTRY,
2024–2031 (USD MILLION) 274
TABLE 274 LATIN AMERICA: BIOMARKERS MARKET FOR LUNG CANCER, BY COUNTRY,
2024–2031 (USD MILLION) 275
TABLE 275 MIDDLE EAST: BIOMARKERS MARKET FOR LUNG CANCER, BY REGION,
2024–2031 (USD MILLION) 275
TABLE 276 GCC COUNTRIES: BIOMARKERS MARKET FOR LUNG CANCER, BY COUNTRY,
2024–2031 (USD MILLION) 275
TABLE 277 BIOMARKERS MARKET FOR COLORECTAL CANCER, BY REGION,
2024–2031 (USD MILLION) 276
TABLE 278 NORTH AMERICA: BIOMARKERS MARKET FOR COLORECTAL CANCER,
BY COUNTRY, 2024–2031 (USD MILLION) 277
TABLE 279 EUROPE: BIOMARKERS MARKET FOR COLORECTAL CANCER, BY COUNTRY,
2024–2031 (USD MILLION) 277
TABLE 280 ASIA PACIFIC: BIOMARKERS MARKET FOR COLORECTAL CANCER, BY COUNTRY, 2024–2031 (USD MILLION) 278
TABLE 281 LATIN AMERICA: BIOMARKERS MARKET FOR COLORECTAL CANCER, BY COUNTRY, 2024–2031 (USD MILLION) 278
TABLE 282 MIDDLE EAST: BIOMARKERS MARKET FOR COLORECTAL CANCER, BY REGION, 2024–2031 (USD MILLION) 279
TABLE 283 GCC COUNTRIES: BIOMARKERS MARKET FOR COLORECTAL CANCER, BY COUNTRY, 2024–2031 (USD MILLION) 279
TABLE 284 BIOMARKERS MARKET FOR PROSTATE CANCER, BY REGION,
2024–2031 (USD MILLION) 280
TABLE 285 NORTH AMERICA: BIOMARKERS MARKET FOR PROSTATE CANCER, BY COUNTRY, 2024–2031 (USD MILLION) 280
TABLE 286 EUROPE: BIOMARKERS MARKET FOR PROSTATE CANCER, BY COUNTRY,
2024–2031 (USD MILLION) 281
TABLE 287 ASIA PACIFIC: BIOMARKERS MARKET FOR PROSTATE CANCER, BY COUNTRY, 2024–2031 (USD MILLION) 281
TABLE 288 LATIN AMERICA: BIOMARKERS MARKET FOR PROSTATE CANCER, BY COUNTRY, 2024–2031 (USD MILLION) 282
TABLE 289 MIDDLE EAST: BIOMARKERS MARKET FOR PROSTATE CANCER, BY REGION,
2024–2031 (USD MILLION) 282
TABLE 290 GCC COUNTRIES: BIOMARKERS MARKET FOR PROSTATE CANCER, BY COUNTRY, 2024–2031 (USD MILLION) 282
TABLE 291 BIOMARKERS MARKET FOR HEMATOLOGICAL CANCER, BY REGION,
2024–2031 (USD MILLION) 283
TABLE 292 NORTH AMERICA: BIOMARKERS MARKET FOR HEMATOLOGICAL CANCER,
BY COUNTRY, 2024–2031 (USD MILLION) 284
TABLE 293 EUROPE: BIOMARKERS MARKET FOR HEMATOLOGICAL CANCER, BY COUNTRY, 2024–2031 (USD MILLION) 284
TABLE 294 ASIA PACIFIC: BIOMARKERS MARKET FOR HEMATOLOGICAL CANCER,
BY COUNTRY, 2024–2031 (USD MILLION) 285
TABLE 295 LATIN AMERICA: BIOMARKERS MARKET FOR HEMATOLOGICAL CANCER,
BY COUNTRY, 2024–2031 (USD MILLION) 285
TABLE 296 MIDDLE EAST: BIOMARKERS MARKET FOR HEMATOLOGICAL CANCER, BY REGION, 2024–2031 (USD MILLION) 286
TABLE 297 GCC COUNTRIES: BIOMARKERS MARKET FOR HEMATOLOGICAL CANCER,
BY COUNTRY, 2024–2031 (USD MILLION) 286
TABLE 298 BIOMARKERS MARKET FOR OTHER CANCERS, BY REGION,
2024–2031 (USD MILLION) 287
TABLE 299 NORTH AMERICA: BIOMARKERS MARKET FOR OTHER CANCERS, BY COUNTRY, 2024–2031 (USD MILLION) 287
TABLE 300 EUROPE: BIOMARKERS MARKET FOR OTHER CANCERS, BY COUNTRY,
2024–2031 (USD MILLION) 288
TABLE 301 ASIA PACIFIC: BIOMARKERS MARKET FOR OTHER CANCERS, BY COUNTRY,
2024–2031 (USD MILLION) 288
TABLE 302 LATIN AMERICA: BIOMARKERS MARKET FOR OTHER CANCERS, BY COUNTRY, 2024–2031 (USD MILLION) 289
TABLE 303 MIDDLE EAST: BIOMARKERS MARKET FOR OTHER CANCERS, BY REGION,
2024–2031 (USD MILLION) 289
TABLE 304 GCC COUNTRIES: BIOMARKERS MARKET FOR OTHER CANCERS, BY COUNTRY, 2024–2031 (USD MILLION) 289
TABLE 305 BIOMARKERS MARKET FOR INFECTIOUS DISEASES, BY TYPE,
2024–2031 (USD MILLION) 291
TABLE 306 BIOMARKERS MARKET FOR INFECTIOUS DISEASES, BY REGION,
2024–2031 (USD MILLION) 291
TABLE 307 NORTH AMERICA: INFECTIOUS DISEASES MARKET FOR INFECTIOUS DISEASES,
BY COUNTRY, 2024–2031 (USD MILLION) 292
TABLE 308 EUROPE: BIOMARKERS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY,
2024–2031 (USD MILLION) 292
TABLE 309 ASIA PACIFIC: BIOMARKERS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2024–2031 (USD MILLION) 293
TABLE 310 LATIN AMERICA: BIOMARKERS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2024–2031 (USD MILLION) 293
TABLE 311 MIDDLE EAST: BIOMARKERS MARKET FOR INFECTIOUS DISEASES, BY REGION, 2024–2031 (USD MILLION) 294
TABLE 312 GCC COUNTRIES: BIOMARKERS MARKET FOR INFECTIOUS DISEASES,
BY COUNTRY, 2024–2031 (USD MILLION) 294
TABLE 313 BIOMARKERS MARKET FOR HIV/AIDS, BY REGION, 2024–2031 (USD MILLION) 295
TABLE 314 NORTH AMERICA: BIOMARKERS MARKET FOR HIV/AIDS, BY COUNTRY,
2024–2031 (USD MILLION) 295
TABLE 315 EUROPE: BIOMARKERS MARKET FOR HIV/AIDS, BY COUNTRY,
2024–2031 (USD MILLION) 296
TABLE 316 ASIA PACIFIC: BIOMARKERS MARKET FOR HIV/AIDS, BY COUNTRY,
2024–2031 (USD MILLION) 296
TABLE 317 LATIN AMERICA: BIOMARKERS MARKET FOR HIV/AIDS, BY COUNTRY,
2024–2031 (USD MILLION) 297
TABLE 318 MIDDLE EAST: BIOMARKERS MARKET FOR HIV/AIDS, BY REGION,
2024–2031 (USD MILLION) 297
TABLE 319 GCC COUNTRIES: BIOMARKERS MARKET FOR HIV/AIDS, BY COUNTRY,
2024–2031 (USD MILLION) 297
TABLE 320 BIOMARKERS MARKET FOR HEPATITIS (B & C), BY REGION,
2024–2031 (USD MILLION) 298
TABLE 321 NORTH AMERICA: BIOMARKERS MARKET FOR HEPATITIS (B & C), BY COUNTRY, 2024–2031 (USD MILLION) 299
TABLE 322 EUROPE: BIOMARKERS MARKET FOR HEPATITIS (B & C), BY COUNTRY,
2024–2031 (USD MILLION) 299
TABLE 323 ASIA PACIFIC: BIOMARKERS MARKET FOR HEPATITIS (B & C), BY COUNTRY,
2024–2031 (USD MILLION) 300
TABLE 324 LATIN AMERICA: BIOMARKERS MARKET FOR HEPATITIS (B & C), BY COUNTRY, 2024–2031 (USD MILLION) 300
TABLE 325 MIDDLE EAST: BIOMARKERS MARKET FOR HEPATITIS (B & C), BY REGION,
2024–2031 (USD MILLION) 301
TABLE 326 GCC COUNTRIES: BIOMARKERS MARKET FOR HEPATITIS (B & C), BY COUNTRY, 2024–2031 (USD MILLION) 301
TABLE 327 BIOMARKERS MARKET FOR RESPIRATORY INFECTIONS, BY REGION,
2024–2031 (USD MILLION) 302
TABLE 328 NORTH AMERICA: BIOMARKERS MARKET FOR RESPIRATORY INFECTIONS,
BY COUNTRY, 2024–2031 (USD MILLION) 302
TABLE 329 EUROPE: BIOMARKERS MARKET FOR RESPIRATORY INFECTIONS, BY COUNTRY, 2024–2031 (USD MILLION) 303
TABLE 330 ASIA PACIFIC: BIOMARKERS MARKET FOR RESPIRATORY INFECTIONS,
BY COUNTRY, 2024–2031 (USD MILLION) 303
TABLE 331 LATIN AMERICA: BIOMARKERS MARKET FOR RESPIRATORY INFECTIONS,
BY COUNTRY, 2024–2031 (USD MILLION) 304
TABLE 332 MIDDLE EAST: BIOMARKERS MARKET FOR RESPIRATORY INFECTIONS, BY REGION, 2024–2031 (USD MILLION) 304
TABLE 333 GCC COUNTRIES: BIOMARKERS MARKET FOR RESPIRATORY INFECTIONS,
BY COUNTRY, 2024–2031 (USD MILLION) 304
TABLE 334 BIOMARKERS MARKET FOR OTHER INFECTIOUS DISEASES, BY REGION,
2024–2031 (USD MILLION) 305
TABLE 335 NORTH AMERICA: BIOMARKERS MARKET FOR OTHER INFECTIOUS DISEASES,
BY COUNTRY, 2024–2031 (USD MILLION) 306
TABLE 336 EUROPE: BIOMARKERS MARKET FOR OTHER INFECTIOUS DISEASES,
BY COUNTRY, 2024–2031 (USD MILLION) 306
TABLE 337 ASIA PACIFIC: BIOMARKERS MARKET FOR OTHER INFECTIOUS DISEASES,
BY COUNTRY, 2024–2031 (USD MILLION) 307
TABLE 338 LATIN AMERICA: BIOMARKERS MARKET FOR OTHER INFECTIOUS DISEASES,
BY COUNTRY, 2024–2031 (USD MILLION) 307
TABLE 339 MIDDLE EAST: BIOMARKERS MARKET FOR OTHER INFECTIOUS DISEASES,
BY REGION, 2024–2031 (USD MILLION) 308
TABLE 340 GCC COUNTRIES: BIOMARKERS MARKET FOR OTHER INFECTIOUS DISEASES,
BY COUNTRY, 2024–2031 (USD MILLION) 308
TABLE 341 BIOMARKERS FOR IMMUNOLOGICAL DISORDERS 309
TABLE 342 BIOMARKERS MARKET FOR IMMUNOLOGICAL DISORDERS, BY TYPE,
2024–2031 (USD MILLION) 309
TABLE 343 BIOMARKERS MARKET FOR IMMUNOLOGICAL DISORDERS, BY REGION,
2024–2031 (USD MILLION) 310
TABLE 344 NORTH AMERICA: BIOMARKERS MARKET FOR IMMUNOLOGICAL DISORDERS,
BY COUNTRY, 2024–2031 (USD MILLION) 310
TABLE 345 EUROPE: BIOMARKERS MARKET FOR IMMUNOLOGICAL DISORDERS,
BY COUNTRY, 2024–2031 (USD MILLION) 311
TABLE 346 ASIA PACIFIC: BIOMARKERS MARKET FOR IMMUNOLOGICAL DISORDERS,
BY COUNTRY, 2024–2031 (USD MILLION) 311
TABLE 347 LATIN AMERICA: BIOMARKERS MARKET FOR IMMUNOLOGICAL DISORDERS,
BY COUNTRY, 2024–2031 (USD MILLION) 312
TABLE 348 MIDDLE EAST: BIOMARKERS MARKET FOR IMMUNOLOGICAL DISORDERS,
BY REGION, 2024–2031 (USD MILLION) 312
TABLE 349 GCC COUNTRIES: BIOMARKERS MARKET FOR IMMUNOLOGICAL DISORDERS,
BY COUNTRY, 2024–2031 (USD MILLION) 312
TABLE 350 BIOMARKERS MARKET FOR RHEUMATOID ARTHRITIS, BY REGION,
2024–2031 (USD MILLION) 313
TABLE 351 NORTH AMERICA: BIOMARKERS MARKET FOR RHEUMATOID ARTHRITIS,
BY COUNTRY, 2024–2031 (USD MILLION) 314
TABLE 352 EUROPE: BIOMARKERS MARKET FOR RHEUMATOID ARTHRITIS, BY COUNTRY, 2024–2031 (USD MILLION) 314
TABLE 353 ASIA PACIFIC: BIOMARKERS MARKET FOR RHEUMATOID ARTHRITIS, BY COUNTRY, 2024–2031 (USD MILLION) 315
TABLE 354 LATIN AMERICA: BIOMARKERS MARKET FOR RHEUMATOID ARTHRITIS,
BY COUNTRY, 2024–2031 (USD MILLION) 315
TABLE 355 MIDDLE EAST: BIOMARKERS MARKET FOR RHEUMATOID ARTHRITIS,
BY REGION, 2024–2031 (USD MILLION) 316
TABLE 356 GCC COUNTRIES: BIOMARKERS MARKET FOR RHEUMATOID ARTHRITIS,
BY COUNTRY, 2024–2031 (USD MILLION) 316
TABLE 357 BIOMARKERS MARKET FOR INFLAMMATORY BOWEL DISEASE, BY REGION,
2024–2031 (USD MILLION) 317
TABLE 358 NORTH AMERICA: BIOMARKERS MARKET FOR INFLAMMATORY BOWEL DISEASE, BY COUNTRY, 2024–2031 (USD MILLION) 317
TABLE 359 EUROPE: BIOMARKERS MARKET FOR INFLAMMATORY BOWEL DISEASE,
BY COUNTRY, 2024–2031 (USD MILLION) 318
TABLE 360 ASIA PACIFIC: BIOMARKERS MARKET FOR INFLAMMATORY BOWEL DISEASE,
BY COUNTRY, 2024–2031 (USD MILLION) 318
TABLE 361 LATIN AMERICA: BIOMARKERS MARKET FOR INFLAMMATORY BOWEL DISEASE,
BY COUNTRY, 2024–2031 (USD MILLION) 319
TABLE 362 MIDDLE EAST: BIOMARKERS MARKET FOR INFLAMMATORY BOWEL DISEASE,
BY REGION, 2024–2031 (USD MILLION) 319
TABLE 363 GCC COUNTRIES: BIOMARKERS MARKET FOR INFLAMMATORY BOWEL DISEASE, BY COUNTRY, 2024–2031 (USD MILLION) 319
TABLE 364 BIOMARKERS MARKET FOR OTHER IMMUNOLOGICAL DISORDERS, BY REGION, 2024–2031 (USD MILLION) 320
TABLE 365 NORTH AMERICA: BIOMARKERS MARKET FOR OTHER IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2024–2031 (USD MILLION) 321
TABLE 366 EUROPE: BIOMARKERS MARKET FOR OTHER IMMUNOLOGICAL DISORDERS,
BY COUNTRY, 2024–2031 (USD MILLION) 321
TABLE 367 ASIA PACIFIC: BIOMARKERS MARKET FOR OTHER IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2024–2031 (USD MILLION) 322
TABLE 368 LATIN AMERICA: BIOMARKERS MARKET FOR OTHER IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2024–2031 (USD MILLION) 322
TABLE 369 MIDDLE EAST: BIOMARKERS MARKET FOR OTHER IMMUNOLOGICAL DISORDERS, BY REGION, 2024–2031 (USD MILLION) 323
TABLE 370 GCC COUNTRIES: BIOMARKERS MARKET FOR OTHER IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2024–2031 (USD MILLION) 323
TABLE 371 BIOMARKERS MARKET FOR NEUROLOGICAL DISORDERS, BY TYPE,
2024–2031 (USD MILLION) 324
TABLE 372 BIOMARKERS MARKET FOR NEUROLOGICAL DISORDERS, BY REGION,
2024–2031 (USD MILLION) 325
TABLE 373 NORTH AMERICA: BIOMARKERS MARKET FOR NEUROLOGICAL DISORDERS,
BY COUNTRY, 2024–2031 (USD MILLION) 325
TABLE 374 EUROPE: BIOMARKERS MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2024–2031 (USD MILLION) 326
TABLE 375 ASIA PACIFIC: BIOMARKERS MARKET FOR NEUROLOGICAL DISORDERS,
BY COUNTRY, 2024–2031 (USD MILLION) 326
TABLE 376 LATIN AMERICA: BIOMARKERS MARKET FOR NEUROLOGICAL DISORDERS,
BY COUNTRY, 2024–2031 (USD MILLION) 327
TABLE 377 MIDDLE EAST: BIOMARKERS MARKET FOR NEUROLOGICAL DISORDERS,
BY REGION, 2024–2031 (USD MILLION) 327
TABLE 378 GCC COUNTRIES: BIOMARKERS MARKET FOR NEUROLOGICAL DISORDERS,
BY COUNTRY, 2024–2031 (USD MILLION) 327
TABLE 379 BIOMARKERS MARKET FOR ALZHEIMER’S DISEASE, BY REGION,
2024–2031 (USD MILLION) 328
TABLE 380 NORTH AMERICA: BIOMARKERS MARKET FOR ALZHEIMER’S DISEASE,
BY COUNTRY, 2024–2031 (USD MILLION) 329
TABLE 381 EUROPE: BIOMARKERS MARKET FOR ALZHEIMER’S DISEASE, BY COUNTRY,
2024–2031 (USD MILLION) 329
TABLE 382 ASIA PACIFIC: BIOMARKERS MARKET FOR ALZHEIMER’S DISEASE, BY COUNTRY, 2024–2031 (USD MILLION) 330
TABLE 383 LATIN AMERICA: BIOMARKERS MARKET FOR ALZHEIMER’S DISEASE, BY COUNTRY, 2024–2031 (USD MILLION) 330
TABLE 384 MIDDLE EAST: BIOMARKERS MARKET FOR ALZHEIMER’S DISEASE, BY REGION, 2024–2031 (USD MILLION) 331
TABLE 385 GCC COUNTRIES: BIOMARKERS MARKET FOR ALZHEIMER’S DISEASE,
BY COUNTRY, 2024–2031 (USD MILLION) 331
TABLE 386 BIOMARKERS MARKET FOR PARKINSON’S DISEASE, BY REGION,
2024–2031 (USD MILLION) 332
TABLE 387 NORTH AMERICA: BIOMARKERS MARKET FOR PARKINSON’S DISEASE,
BY COUNTRY, 2024–2031 (USD MILLION) 332
TABLE 388 EUROPE: BIOMARKERS MARKET FOR PARKINSON’S DISEASE, BY COUNTRY, 2024–2031 (USD MILLION) 333
TABLE 389 ASIA PACIFIC: BIOMARKERS MARKET FOR PARKINSON’S DISEASE, BY COUNTRY, 2024–2031 (USD MILLION) 333
TABLE 390 LATIN AMERICA: BIOMARKERS MARKET FOR PARKINSON’S DISEASE, BY COUNTRY, 2024–2031 (USD MILLION) 334
TABLE 391 MIDDLE EAST: BIOMARKERS MARKET FOR PARKINSON’S DISEASE, BY REGION, 2024–2031 (USD MILLION) 334
TABLE 392 GCC COUNTRIES: BIOMARKERS MARKET FOR PARKINSON’S DISEASE,
BY COUNTRY, 2024–2031 (USD MILLION) 334
TABLE 393 BIOMARKERS MARKET FOR MULTIPLE SCLEROSIS, BY REGION,
2024–2031 (USD MILLION) 335
TABLE 394 NORTH AMERICA: BIOMARKERS MARKET FOR MULTIPLE SCLEROSIS,
BY COUNTRY, 2024–2031 (USD MILLION) 335
TABLE 395 EUROPE: BIOMARKERS MARKET FOR MULTIPLE SCLEROSIS, BY COUNTRY,
2024–2031 (USD MILLION) 336
TABLE 396 ASIA PACIFIC: BIOMARKERS MARKET FOR MULTIPLE SCLEROSIS, BY COUNTRY, 2024–2031 (USD MILLION) 336
TABLE 397 LATIN AMERICA: BIOMARKERS MARKET FOR MULTIPLE SCLEROSIS, BY COUNTRY, 2024–2031 (USD MILLION) 337
TABLE 398 MIDDLE EAST: BIOMARKERS MARKET FOR MULTIPLE SCLEROSIS, BY REGION, 2024–2031 (USD MILLION) 337
TABLE 399 GCC COUNTRIES: BIOMARKERS MARKET FOR MULTIPLE SCLEROSIS, BY COUNTRY, 2024–2031 (USD MILLION) 337
TABLE 400 BIOMARKERS MARKET FOR OTHER NEUROLOGICAL DISORDERS, BY REGION, 2024–2031 (USD MILLION) 338
TABLE 401 NORTH AMERICA: BIOMARKERS MARKET FOR OTHER NEUROLOGICAL DISORDERS, BY COUNTRY, 2024–2031 (USD MILLION) 339
TABLE 402 EUROPE: BIOMARKERS MARKET FOR OTHER NEUROLOGICAL DISORDERS,
BY COUNTRY, 2024–2031 (USD MILLION) 339
TABLE 403 ASIA PACIFIC: BIOMARKERS MARKET FOR OTHER NEUROLOGICAL DISORDERS,
BY COUNTRY, 2024–2031 (USD MILLION) 340
TABLE 404 LATIN AMERICA: BIOMARKERS MARKET FOR OTHER NEUROLOGICAL DISORDERS, BY COUNTRY, 2024–2031 (USD MILLION) 340
TABLE 405 MIDDLE EAST: BIOMARKERS MARKET FOR OTHER NEUROLOGICAL DISORDERS,
BY REGION, 2024–2031 (USD MILLION) 341
TABLE 406 GCC COUNTRIES: BIOMARKERS MARKET FOR OTHER NEUROLOGICAL DISORDERS, BY COUNTRY, 2024–2031 (USD MILLION) 341
TABLE 407 BIOMARKERS MARKET FOR METABOLIC & ENDOCRINE DISORDERS, BY TYPE, 2024–2031 (USD MILLION) 342
TABLE 408 BIOMARKERS MARKET FOR METABOLIC & ENDOCRINE DISORDERS, BY REGION, 2024–2031 (USD MILLION) 342
TABLE 409 NORTH AMERICA: BIOMARKERS MARKET FOR METABOLIC & ENDOCRINE DISORDERS, BY COUNTRY, 2024–2031 (USD MILLION) 343
TABLE 410 EUROPE: BIOMARKERS MARKET FOR METABOLIC & ENDOCRINE DISORDERS,
BY COUNTRY, 2024–2031 (USD MILLION) 343
TABLE 411 ASIA PACIFIC: BIOMARKERS MARKET FOR METABOLIC & ENDOCRINE DISORDERS, BY COUNTRY, 2024–2031 (USD MILLION) 344
TABLE 412 LATIN AMERICA: BIOMARKERS MARKET FOR METABOLIC & ENDOCRINE DISORDERS, BY COUNTRY, 2024–2031 (USD MILLION) 344
TABLE 413 MIDDLE EAST: BIOMARKERS MARKET FOR METABOLIC & ENDOCRINE DISORDERS, BY REGION, 2024–2031 (USD MILLION) 345
TABLE 414 GCC COUNTRIES: BIOMARKERS MARKET FOR METABOLIC & ENDOCRINE DISORDERS, BY COUNTRY, 2024–2031 (USD MILLION) 345
TABLE 415 BIOMARKERS MARKET FOR DIABETES, BY REGION, 2024–2031 (USD MILLION) 346
TABLE 416 NORTH AMERICA: BIOMARKERS MARKET FOR DIABETES, BY COUNTRY,
2024–2031 (USD MILLION) 346
TABLE 417 EUROPE: BIOMARKERS MARKET FOR DIABETES, BY COUNTRY,
2024–2031 (USD MILLION) 347
TABLE 418 ASIA PACIFIC: BIOMARKERS MARKET FOR DIABETES, BY COUNTRY,
2024–2031 (USD MILLION) 347
TABLE 419 LATIN AMERICA: BIOMARKERS MARKET FOR DIABETES, BY COUNTRY,
2024–2031 (USD MILLION) 348
TABLE 420 MIDDLE EAST: BIOMARKERS MARKET FOR DIABETES, BY REGION,
2024–2031 (USD MILLION) 348
TABLE 421 GCC COUNTRIES: BIOMARKERS MARKET FOR DIABETES, BY COUNTRY,
2024–2031 (USD MILLION) 348
TABLE 422 BIOMARKERS MARKET FOR OBESITY, BY REGION, 2024–2031 (USD MILLION) 349
TABLE 423 NORTH AMERICA: BIOMARKERS MARKET FOR OBESITY, BY COUNTRY,
2024–2031 (USD MILLION) 350
TABLE 424 EUROPE: BIOMARKERS MARKET FOR OBESITY, BY COUNTRY,
2024–2031 (USD MILLION) 350
TABLE 425 ASIA PACIFIC: BIOMARKERS MARKET FOR OBESITY, BY COUNTRY,
2024–2031 (USD MILLION) 351
TABLE 426 LATIN AMERICA: BIOMARKERS MARKET FOR OBESITY, BY COUNTRY,
2024–2031 (USD MILLION) 351
TABLE 427 MIDDLE EAST: BIOMARKERS MARKET FOR OBESITY, BY REGION,
2024–2031 (USD MILLION) 352
TABLE 428 GCC COUNTRIES: BIOMARKERS MARKET FOR OBESITY, BY COUNTRY,
2024–2031 (USD MILLION) 352
TABLE 429 BIOMARKERS MARKET FOR OTHER METABOLIC & ENDOCRINE DISORDERS,
BY REGION, 2024–2031 (USD MILLION) 353
TABLE 430 NORTH AMERICA: BIOMARKERS MARKET FOR OTHER METABOLIC & ENDOCRINE DISORDERS, BY COUNTRY, 2024–2031 (USD MILLION) 353
TABLE 431 EUROPE: BIOMARKERS MARKET FOR OTHER METABOLIC & ENDOCRINE DISORDERS, BY COUNTRY, 2024–2031 (USD MILLION) 354
TABLE 432 ASIA PACIFIC: BIOMARKERS MARKET FOR OTHER METABOLIC & ENDOCRINE DISORDERS, BY COUNTRY, 2024–2031 (USD MILLION) 354
TABLE 433 LATIN AMERICA: BIOMARKERS MARKET FOR OTHER METABOLIC & ENDOCRINE DISORDERS, BY COUNTRY, 2024–2031 (USD MILLION) 354
TABLE 434 MIDDLE EAST: BIOMARKERS MARKET FOR OTHER METABOLIC & ENDOCRINE DISORDERS, BY REGION, 2024–2031 (USD MILLION) 355
TABLE 435 GCC COUNTRIES: BIOMARKERS MARKET FOR OTHER METABOLIC & ENDOCRINE DISORDERS, BY COUNTRY, 2024–2031 (USD MILLION) 355
TABLE 436 BIOMARKERS FOR CARDIOVASCULAR DISORDERS 356
TABLE 437 BIOMARKERS MARKET FOR CARDIOVASCULAR DISORDERS, BY REGION,
2024–2031 (USD MILLION) 357
TABLE 438 NORTH AMERICA: BIOMARKERS MARKET FOR CARDIOVASCULAR DISORDERS,
BY COUNTRY, 2024–2031 (USD MILLION) 357
TABLE 439 EUROPE: BIOMARKERS MARKET FOR CARDIOVASCULAR DISORDERS,
BY COUNTRY, 2024–2031 (USD MILLION) 358
TABLE 440 ASIA PACIFIC: BIOMARKERS MARKET FOR CARDIOVASCULAR DISORDERS,
BY COUNTRY, 2024–2031 (USD MILLION) 358
TABLE 441 LATIN AMERICA: BIOMARKERS MARKET FOR CARDIOVASCULAR DISORDERS,
BY COUNTRY, 2024–2031 (USD MILLION) 359
TABLE 442 MIDDLE EAST: BIOMARKERS MARKET FOR CARDIOVASCULAR DISORDERS,
BY REGION, 2024–2031 (USD MILLION) 359
TABLE 443 GCC COUNTRIES: BIOMARKERS MARKET FOR CARDIOVASCULAR DISORDERS,
BY COUNTRY, 2024–2031 (USD MILLION) 359
TABLE 444 BIOMARKERS FOR RENAL DISORDERS 360
TABLE 445 BIOMARKERS MARKET FOR OTHER DISEASE INDICATIONS, BY REGION,
2024–2031 (USD MILLION) 361
TABLE 446 NORTH AMERICA: BIOMARKERS MARKET FOR OTHER DISEASE INDICATIONS,
BY COUNTRY, 2024–2031 (USD MILLION) 361
TABLE 447 EUROPE: BIOMARKERS MARKET FOR OTHER DISEASE INDICATIONS,
BY COUNTRY, 2024–2031 (USD MILLION) 362
TABLE 448 ASIA PACIFIC: BIOMARKERS MARKET FOR OTHER DISEASE INDICATIONS,
BY COUNTRY, 2024–2031 (USD MILLION) 362
TABLE 449 LATIN AMERICA: BIOMARKERS MARKET FOR OTHER DISEASE INDICATIONS,
BY COUNTRY, 2024–2031 (USD MILLION) 363
TABLE 450 MIDDLE EAST: BIOMARKERS MARKET FOR OTHER DISEASE INDICATIONS,
BY REGION, 2024–2031 (USD MILLION) 363
TABLE 451 GCC COUNTRIES: BIOMARKERS MARKET FOR OTHER DISEASE INDICATIONS,
BY COUNTRY, 2024–2031 (USD MILLION) 363
TABLE 452 BIOMARKERS MARKET, BY END USER, 2024–2031 (USD MILLION) 365
TABLE 453 BIOMARKERS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2024–2031 (USD MILLION) 366
TABLE 454 NORTH AMERICA: BIOMARKERS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION) 367
TABLE 455 EUROPE: BIOMARKERS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION) 367
TABLE 456 ASIA PACIFIC: BIOMARKERS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION) 368
TABLE 457 LATIN AMERICA: BIOMARKERS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION) 368
TABLE 458 MIDDLE EAST: BIOMARKERS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2024–2031 (USD MILLION) 369
TABLE 459 GCC COUNTRIES: BIOMARKERS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION) 369
TABLE 460 BIOMARKERS MARKET FOR HOSPITALS & DIAGNOSTIC LABORATORIES, BY REGION, 2024–2031 (USD MILLION) 370
TABLE 461 NORTH AMERICA: BIOMARKERS MARKET FOR HOSPITALS & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION) 371
TABLE 462 EUROPE: BIOMARKERS MARKET FOR HOSPITALS & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION) 371
TABLE 463 ASIA PACIFIC: BIOMARKERS MARKET FOR HOSPITALS & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION) 372
TABLE 464 LATIN AMERICA: BIOMARKERS MARKET FOR HOSPITALS & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION) 372
TABLE 465 MIDDLE EAST: BIOMARKERS MARKET FOR HOSPITALS & DIAGNOSTIC LABORATORIES, BY REGION, 2024–2031 (USD MILLION) 373
TABLE 466 GCC COUNTRIES: BIOMARKERS MARKET FOR HOSPITALS & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION) 373
TABLE 467 BIOMARKERS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2024–2031 (USD MILLION) 374
TABLE 468 NORTH AMERICA: BIOMARKERS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION) 374
TABLE 469 EUROPE: BIOMARKERS MARKET FOR ACADEMIC & RESEARCH INSTITUTES,
BY COUNTRY, 2024–2031 (USD MILLION) 375
TABLE 470 ASIA PACIFIC: BIOMARKERS MARKET FOR ACADEMIC & RESEARCH INSTITUTES,
BY COUNTRY, 2024–2031 (USD MILLION) 375
TABLE 471 LATIN AMERICA: BIOMARKERS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION) 375
TABLE 472 MIDDLE EAST: BIOMARKERS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2024–2031 (USD MILLION) 376
TABLE 473 GCC COUNTRIES: BIOMARKERS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION) 376
TABLE 474 BIOMARKERS MARKET FOR OTHER END USERS, BY REGION,
2024–2031 (USD MILLION) 378
TABLE 475 NORTH AMERICA: BIOMARKERS MARKET FOR OTHER END USERS, BY COUNTRY, 2024–2031 (USD MILLION) 378
TABLE 476 EUROPE: BIOMARKERS MARKET FOR OTHER END USERS, BY COUNTRY,
2024–2031 (USD MILLION) 379
TABLE 477 ASIA PACIFIC: BIOMARKERS MARKET FOR OTHER END USERS, BY COUNTRY, 2024–2031 (USD MILLION) 379
TABLE 478 LATIN AMERICA: BIOMARKERS MARKET FOR OTHER END USERS, BY COUNTRY, 2024–2031 (USD MILLION) 380
TABLE 479 MIDDLE EAST: BIOMARKERS MARKET FOR OTHER END USERS, BY REGION,
2024–2031 (USD MILLION) 380
TABLE 480 GCC COUNTRIES: BIOMARKERS MARKET FOR OTHER END USERS, BY COUNTRY, 2024–2031 (USD MILLION) 380
TABLE 481 BIOMARKERS MARKET, BY REGION, 2024–2031 (USD MILLION) 382
TABLE 482 NORTH AMERICA: BIOMARKERS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 383
TABLE 483 NORTH AMERICA: BIOMARKERS MARKET, BY OFFERING,
2024–2031 (USD MILLION) 384
TABLE 484 NORTH AMERICA: BIOMARKER CONSUMABLES MARKET, BY TYPE,
2024–2031 (USD MILLION) 384
TABLE 485 NORTH AMERICA: BIOMARKERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 384
TABLE 486 NORTH AMERICA: EFFICACY BIOMARKERS MARKET, BY TYPE,
2024–2031 (USD MILLION) 385
TABLE 487 NORTH AMERICA: BIOMARKERS MARKET, BY RESEARCH AREA,
2024–2031 (USD MILLION) 385
TABLE 488 NORTH AMERICA: BIOMARKERS MARKET, BY TECHNOLOGY,
2024–2031 (USD MILLION) 386
TABLE 489 NORTH AMERICA: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE,
2024–2031 (USD MILLION) 386
TABLE 490 NORTH AMERICA: BIOMARKERS MARKET, BY DISEASE INDICATION,
2024–2031 (USD MILLION) 387
TABLE 491 NORTH AMERICA: BIOMARKERS MARKET FOR CANCER, BY TYPE,
2024–2031 (USD MILLION) 387
TABLE 492 NORTH AMERICA: BIOMARKERS MARKET FOR INFECTIOUS DISEASES,
BY TYPE, 2024–2031 (USD MILLION) 388
TABLE 493 NORTH AMERICA: BIOMARKERS MARKET FOR IMMUNOLOGICAL DISORDERS,
BY TYPE, 2024–2031 (USD MILLION) 388
TABLE 494 NORTH AMERICA: BIOMARKERS MARKET FOR NEUROLOGICAL DISORDERS,
BY TYPE, 2024–2031 (USD MILLION) 389
TABLE 495 NORTH AMERICA: BIOMARKERS MARKET FOR METABOLIC & ENDOCRINE DISORDERS, BY TYPE, 2024–2031 (USD MILLION) 389
TABLE 496 NORTH AMERICA: BIOMARKERS MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 390
TABLE 497 NORTH AMERICA: BIOMARKERS MARKET, BY END USER,
2024–2031 (USD MILLION) 390
TABLE 498 US: BIOMARKERS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 391
TABLE 499 US: BIOMARKER CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION) 392
TABLE 500 US: BIOMARKERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 392
TABLE 501 US: EFFICACY BIOMARKERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 392
TABLE 502 US: BIOMARKERS MARKET, BY RESEARCH AREA, 2024–2031 (USD MILLION) 392
TABLE 503 US: BIOMARKERS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 393
TABLE 504 US: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE,
2024–2031 (USD MILLION) 394
TABLE 505 US: BIOMARKERS MARKET, BY DISEASE INDICATION, 2024–2031 (USD MILLION) 394
TABLE 506 US: BIOMARKERS MARKET FOR CANCER, BY TYPE, 2024–2031 (USD MILLION) 395
TABLE 507 US: BIOMARKERS MARKET FOR INFECTIOUS DISEASES, BY TYPE,
2024–2031 (USD MILLION) 395
TABLE 508 US: BIOMARKERS MARKET FOR IMMUNOLOGICAL DISORDERS, BY TYPE,
2024–2031 (USD MILLION) 396
TABLE 509 US: BIOMARKERS MARKET FOR NEUROLOGICAL DISORDERS, BY TYPE,
2024–2031 (USD MILLION) 396
TABLE 510 US: BIOMARKERS MARKET FOR METABOLIC & ENDOCRINE DISORDERS, BY TYPE, 2024–2031 (USD MILLION) 397
TABLE 511 US: BIOMARKERS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 397
TABLE 512 US: BIOMARKERS MARKET, BY END USER, 2024–2031 (USD MILLION) 398
TABLE 513 CANADA: BIOMARKERS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 399
TABLE 514 CANADA: BIOMARKER CONSUMABLES MARKET, BY TYPE,
2024–2031 (USD MILLION) 399
TABLE 515 CANADA: BIOMARKERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 400
TABLE 516 CANADA: EFFICACY BIOMARKERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 400
TABLE 517 CANADA: BIOMARKERS MARKET, BY RESEARCH AREA, 2024–2031 (USD MILLION) 400
TABLE 518 CANADA: BIOMARKERS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 401
TABLE 519 CANADA: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE,
2024–2031 (USD MILLION) 401
TABLE 520 CANADA: BIOMARKERS MARKET, BY DISEASE INDICATION,
2024–2031 (USD MILLION) 402
TABLE 521 CANADA: BIOMARKERS MARKET FOR CANCER, BY TYPE,
2024–2031 (USD MILLION) 402
TABLE 522 CANADA: BIOMARKERS MARKET FOR INFECTIOUS DISEASES, BY TYPE,
2024–2031 (USD MILLION) 403
TABLE 523 CANADA: BIOMARKERS MARKET FOR IMMUNOLOGICAL DISORDERS, BY TYPE, 2024–2031 (USD MILLION) 403
TABLE 524 CANADA: BIOMARKERS MARKET FOR NEUROLOGICAL DISORDERS, BY TYPE, 2024–2031 (USD MILLION) 404
TABLE 525 CANADA: BIOMARKERS MARKET FOR METABOLIC & ENDOCRINE DISORDERS,
BY TYPE, 2024–2031 (USD MILLION) 404
TABLE 526 CANADA: BIOMARKERS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 405
TABLE 527 CANADA: BIOMARKERS MARKET, BY END USER, 2024–2031 (USD MILLION) 405
TABLE 528 EUROPE: BIOMARKERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 406
TABLE 529 EUROPE: BIOMARKERS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 406
TABLE 530 EUROPE: BIOMARKER CONSUMABLES MARKET, BY TYPE,
2024–2031 (USD MILLION) 407
TABLE 531 EUROPE: BIOMARKERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 407
TABLE 532 EUROPE: EFFICACY BIOMARKERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 408
TABLE 533 EUROPE: BIOMARKERS MARKET, BY RESEARCH AREA, 2024–2031 (USD MILLION) 408
TABLE 534 EUROPE: BIOMARKERS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 409
TABLE 535 EUROPE: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE,
2024–2031 (USD MILLION) 409
TABLE 536 EUROPE: BIOMARKERS MARKET, BY DISEASE INDICATION,
2024–2031 (USD MILLION) 410
TABLE 537 EUROPE: BIOMARKERS MARKET FOR CANCER, BY TYPE,
2024–2031 (USD MILLION) 410
TABLE 538 EUROPE: BIOMARKERS MARKET FOR INFECTIOUS DISEASES,
BY TYPE, 2024–2031 (USD MILLION) 411
TABLE 539 EUROPE: BIOMARKERS MARKET FOR IMMUNOLOGICAL DISORDERS,
BY TYPE, 2024–2031 (USD MILLION) 411
TABLE 540 EUROPE: BIOMARKERS MARKET FOR NEUROLOGICAL DISORDERS,
BY TYPE, 2024–2031 (USD MILLION) 412
TABLE 541 EUROPE: BIOMARKERS MARKET FOR METABOLIC & ENDOCRINE DISORDERS,
BY TYPE, 2024–2031 (USD MILLION) 412
TABLE 542 EUROPE: BIOMARKERS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 413
TABLE 543 EUROPE: BIOMARKERS MARKET, BY END USER, 2024–2031 (USD MILLION) 413
TABLE 544 GERMANY: BIOMARKERS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 414
TABLE 545 GERMANY: BIOMARKER CONSUMABLES MARKET, BY TYPE,
2024–2031 (USD MILLION) 415
TABLE 546 GERMANY: BIOMARKERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 415
TABLE 547 GERMANY: EFFICACY BIOMARKERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 416
TABLE 548 GERMANY: BIOMARKERS MARKET, BY RESEARCH AREA,
2024–2031 (USD MILLION) 416
TABLE 549 GERMANY: BIOMARKERS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 417
TABLE 550 GERMANY: BIOMARKERS MARKET FOR IMMUNOASSAYS,
BY TYPE, 2024–2031 (USD MILLION) 417
TABLE 551 GERMANY: BIOMARKERS MARKET, BY DISEASE INDICATION,
2024–2031 (USD MILLION) 418
TABLE 552 GERMANY: BIOMARKERS MARKET FOR CANCER, BY TYPE,
2024–2031 (USD MILLION) 418
TABLE 553 GERMANY: BIOMARKERS MARKET FOR INFECTIOUS DISEASES, BY TYPE,
2024–2031 (USD MILLION) 419
TABLE 554 GERMANY: BIOMARKERS MARKET FOR IMMUNOLOGICAL DISORDERS, BY TYPE, 2024–2031 (USD MILLION) 419
TABLE 555 GERMANY: BIOMARKERS MARKET FOR NEUROLOGICAL DISORDERS, BY TYPE, 2024–2031 (USD MILLION) 420
TABLE 556 GERMANY: BIOMARKERS MARKET FOR METABOLIC & ENDOCRINE DISORDERS,
BY TYPE, 2024–2031 (USD MILLION) 420
TABLE 557 GERMANY: BIOMARKERS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 421
TABLE 558 GERMANY: BIOMARKERS MARKET, BY END USER, 2024–2031 (USD MILLION) 421
TABLE 559 UK: BIOMARKERS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 422
TABLE 560 UK: BIOMARKER CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION) 423
TABLE 561 UK: BIOMARKERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 423
TABLE 562 UK: EFFICACY BIOMARKERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 423
TABLE 563 UK: BIOMARKERS MARKET, BY RESEARCH AREA, 2024–2031 (USD MILLION) 423
TABLE 564 UK: BIOMARKERS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 424
TABLE 565 UK: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE,
2024–2031 (USD MILLION) 425
TABLE 566 UK: BIOMARKERS MARKET, BY DISEASE INDICATION, 2024–2031 (USD MILLION) 425
TABLE 567 UK: BIOMARKERS MARKET FOR CANCER, BY TYPE, 2024–2031 (USD MILLION) 426
TABLE 568 UK: BIOMARKERS MARKET FOR INFECTIOUS DISEASES, BY TYPE,
2024–2031 (USD MILLION) 426
TABLE 569 UK: BIOMARKERS MARKET FOR IMMUNOLOGICAL DISORDERS,
BY TYPE, 2024–2031 (USD MILLION) 427
TABLE 570 UK: BIOMARKERS MARKET FOR NEUROLOGICAL DISORDERS,
BY TYPE, 2024–2031 (USD MILLION) 427
TABLE 571 UK: BIOMARKERS MARKET FOR METABOLIC & ENDOCRINE DISORDERS, BY TYPE, 2024–2031 (USD MILLION) 428
TABLE 572 UK: BIOMARKERS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 428
TABLE 573 UK: BIOMARKERS MARKET, BY END USER, 2024–2031 (USD MILLION) 429
TABLE 574 FRANCE: BIOMARKERS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 430
TABLE 575 FRANCE: BIOMARKER CONSUMABLES MARKET, BY TYPE,
2024–2031 (USD MILLION) 430
TABLE 576 FRANCE: BIOMARKERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 430
TABLE 577 FRANCE: EFFICACY BIOMARKERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 431
TABLE 578 FRANCE: BIOMARKERS MARKET, BY RESEARCH AREA, 2024–2031 (USD MILLION) 431
TABLE 579 FRANCE: BIOMARKERS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 432
TABLE 580 FRANCE: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE,
2024–2031 (USD MILLION) 432
TABLE 581 FRANCE: BIOMARKERS MARKET, BY DISEASE INDICATION,
2024–2031 (USD MILLION) 433
TABLE 582 FRANCE: BIOMARKERS MARKET FOR CANCER, BY TYPE,
2024–2031 (USD MILLION) 433
TABLE 583 FRANCE: BIOMARKERS MARKET FOR INFECTIOUS DISEASES, BY TYPE,
2024–2031 (USD MILLION) 434
TABLE 584 FRANCE: BIOMARKERS MARKET FOR IMMUNOLOGICAL DISORDERS, BY TYPE, 2024–2031 (USD MILLION) 434
TABLE 585 FRANCE: BIOMARKERS MARKET FOR NEUROLOGICAL DISORDERS, BY TYPE, 2024–2031 (USD MILLION) 435
TABLE 586 FRANCE: BIOMARKERS MARKET FOR METABOLIC & ENDOCRINE DISORDERS,
BY TYPE, 2024–2031 (USD MILLION) 435
TABLE 587 FRANCE: BIOMARKERS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 436
TABLE 588 FRANCE: BIOMARKERS MARKET, BY END USER, 2024–2031 (USD MILLION) 436
TABLE 589 ITALY: BIOMARKERS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 437
TABLE 590 ITALY: BIOMARKER CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION) 437
TABLE 591 ITALY: BIOMARKERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 437
TABLE 592 ITALY: EFFICACY BIOMARKERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 438
TABLE 593 ITALY: BIOMARKERS MARKET, BY RESEARCH AREA, 2024–2031 (USD MILLION) 438
TABLE 594 ITALY: BIOMARKERS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 439
TABLE 595 ITALY: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE,
2024–2031 (USD MILLION) 439
TABLE 596 ITALY: BIOMARKERS MARKET, BY DISEASE INDICATION,
2024–2031 (USD MILLION) 440
TABLE 597 ITALY: BIOMARKERS MARKET FOR CANCER, BY TYPE, 2024–2031 (USD MILLION) 440
TABLE 598 ITALY: BIOMARKERS MARKET FOR INFECTIOUS DISEASES, BY TYPE,
2024–2031 (USD MILLION) 441
TABLE 599 ITALY: BIOMARKERS MARKET FOR IMMUNOLOGICAL DISORDERS, BY TYPE,
2024–2031 (USD MILLION) 441
TABLE 600 ITALY: BIOMARKERS MARKET FOR NEUROLOGICAL DISORDERS, BY TYPE,
2024–2031 (USD MILLION) 442
TABLE 601 ITALY: BIOMARKERS MARKET FOR METABOLIC & ENDOCRINE DISORDERS,
BY TYPE, 2024–2031 (USD MILLION) 442
TABLE 602 ITALY: BIOMARKERS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 443
TABLE 603 ITALY: BIOMARKERS MARKET, BY END USER, 2024–2031 (USD MILLION) 443
TABLE 604 SPAIN: BIOMARKERS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 444
TABLE 605 SPAIN: BIOMARKER CONSUMABLES MARKET, BY TYPE,
2024–2031 (USD MILLION) 444
TABLE 606 SPAIN: BIOMARKERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 445
TABLE 607 SPAIN: EFFICACY BIOMARKERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 445
TABLE 608 SPAIN: BIOMARKERS MARKET, BY RESEARCH AREA, 2024–2031 (USD MILLION) 445
TABLE 609 SPAIN: BIOMARKERS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 446
TABLE 610 SPAIN: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE,
2024–2031 (USD MILLION) 446
TABLE 611 SPAIN: BIOMARKERS MARKET, BY DISEASE INDICATION,
2024–2031 (USD MILLION) 447
TABLE 612 SPAIN: BIOMARKERS MARKET FOR CANCER, BY TYPE, 2024–2031 (USD MILLION) 447
TABLE 613 SPAIN: BIOMARKERS MARKET FOR INFECTIOUS DISEASES, BY TYPE,
2024–2031 (USD MILLION) 448
TABLE 614 SPAIN: BIOMARKERS MARKET FOR IMMUNOLOGICAL DISORDERS, BY TYPE, 2024–2031 (USD MILLION) 448
TABLE 615 SPAIN: BIOMARKERS MARKET FOR NEUROLOGICAL DISORDERS, BY TYPE,
2024–2031 (USD MILLION) 449
TABLE 616 SPAIN: BIOMARKERS MARKET FOR METABOLIC & ENDOCRINE DISORDERS,
BY TYPE, 2024–2031 (USD MILLION) 449
TABLE 617 SPAIN: BIOMARKERS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 450
TABLE 618 SPAIN: BIOMARKERS MARKET, BY END USER, 2024–2031 (USD MILLION) 450
TABLE 619 REST OF EUROPE: BIOMARKERS MARKET, BY OFFERING,
2024–2031 (USD MILLION) 451
TABLE 620 REST OF EUROPE: BIOMARKER CONSUMABLES MARKET, BY TYPE,
2024–2031 (USD MILLION) 451
TABLE 621 REST OF EUROPE: BIOMARKERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 452
TABLE 622 REST OF EUROPE: EFFICACY BIOMARKERS MARKET, BY TYPE,
2024–2031 (USD MILLION) 452
TABLE 623 REST OF EUROPE: BIOMARKERS MARKET, BY RESEARCH AREA,
2024–2031 (USD MILLION) 453
TABLE 624 REST OF EUROPE: BIOMARKERS MARKET, BY TECHNOLOGY,
2024–2031 (USD MILLION) 453
TABLE 625 REST OF EUROPE: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE,
2024–2031 (USD MILLION) 454
TABLE 626 REST OF EUROPE: BIOMARKERS MARKET, BY DISEASE INDICATION,
2024–2031 (USD MILLION) 454
TABLE 627 REST OF EUROPE: BIOMARKERS MARKET FOR CANCER, BY TYPE,
2024–2031 (USD MILLION) 455
TABLE 628 REST OF EUROPE: BIOMARKERS MARKET FOR INFECTIOUS DISEASES,
BY TYPE, 2024–2031 (USD MILLION) 455
TABLE 629 REST OF EUROPE: BIOMARKERS MARKET FOR IMMUNOLOGICAL DISORDERS,
BY TYPE, 2024–2031 (USD MILLION) 456
TABLE 630 REST OF EUROPE: BIOMARKERS MARKET FOR NEUROLOGICAL DISORDERS,
BY TYPE, 2024–2031 (USD MILLION) 456
TABLE 631 REST OF EUROPE: BIOMARKERS MARKET FOR METABOLIC & ENDOCRINE DISORDERS, BY TYPE, 2024–2031 (USD MILLION) 457
TABLE 632 REST OF EUROPE: BIOMARKERS MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 457
TABLE 633 REST OF EUROPE: BIOMARKERS MARKET, BY END USER,
2024–2031 (USD MILLION) 458
TABLE 634 ASIA PACIFIC: BIOMARKERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 460
TABLE 635 ASIA PACIFIC: BIOMARKERS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 460
TABLE 636 ASIA PACIFIC: BIOMARKER CONSUMABLES MARKET, BY TYPE,
2024–2031 (USD MILLION) 461
TABLE 637 ASIA PACIFIC: BIOMARKERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 461
TABLE 638 ASIA PACIFIC: EFFICACY BIOMARKERS MARKET, BY TYPE,
2024–2031 (USD MILLION) 462
TABLE 639 ASIA PACIFIC: BIOMARKERS MARKET, BY RESEARCH AREA,
2024–2031 (USD MILLION) 462
TABLE 640 ASIA PACIFIC: BIOMARKERS MARKET, BY TECHNOLOGY,
2024–2031 (USD MILLION) 463
TABLE 641 ASIA PACIFIC: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE,
2024–2031 (USD MILLION) 463
TABLE 642 ASIA PACIFIC: BIOMARKERS MARKET, BY DISEASE INDICATION,
2024–2031 (USD MILLION) 464
TABLE 643 ASIA PACIFIC: BIOMARKERS MARKET FOR CANCER, BY TYPE,
2024–2031 (USD MILLION) 464
TABLE 644 ASIA PACIFIC: BIOMARKERS MARKET FOR INFECTIOUS DISEASES, BY TYPE,
2024–2031 (USD MILLION) 465
TABLE 645 ASIA PACIFIC: BIOMARKERS MARKET FOR IMMUNOLOGICAL DISORDERS, BY TYPE, 2024–2031 (USD MILLION) 465
TABLE 646 ASIA PACIFIC: BIOMARKERS MARKET FOR NEUROLOGICAL DISORDERS, BY TYPE, 2024–2031 (USD MILLION) 466
TABLE 647 ASIA PACIFIC: BIOMARKERS MARKET FOR METABOLIC & ENDOCRINE DISORDERS, BY TYPE, 2024–2031 (USD MILLION) 466
TABLE 648 ASIA PACIFIC: BIOMARKERS MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 467
TABLE 649 ASIA PACIFIC: BIOMARKERS MARKET, BY END USER, 2024–2031 (USD MILLION) 467
TABLE 650 CHINA: BIOMARKERS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 468
TABLE 651 CHINA: BIOMARKER CONSUMABLES MARKET, BY TYPE,
2024–2031 (USD MILLION) 468
TABLE 652 CHINA: BIOMARKERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 469
TABLE 653 CHINA: EFFICACY BIOMARKERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 469
TABLE 654 CHINA: BIOMARKERS MARKET, BY RESEARCH AREA, 2024–2031 (USD MILLION) 469
TABLE 655 CHINA: BIOMARKERS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 470
TABLE 656 CHINA: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE,
2024–2031 (USD MILLION) 470
TABLE 657 CHINA: BIOMARKERS MARKET, BY DISEASE INDICATION,
2024–2031 (USD MILLION) 471
TABLE 658 CHINA: BIOMARKERS MARKET FOR CANCER, BY TYPE, 2024–2031 (USD MILLION) 471
TABLE 659 CHINA: BIOMARKERS MARKET FOR INFECTIOUS DISEASES, BY TYPE,
2024–2031 (USD MILLION) 472
TABLE 660 CHINA: BIOMARKERS MARKET FOR IMMUNOLOGICAL DISORDERS, BY TYPE, 2024–2031 (USD MILLION) 472
TABLE 661 CHINA: BIOMARKERS MARKET FOR NEUROLOGICAL DISORDERS, BY TYPE,
2024–2031 (USD MILLION) 473
TABLE 662 CHINA: BIOMARKERS MARKET FOR METABOLIC & ENDOCRINE DISORDERS,
BY TYPE, 2024–2031 (USD MILLION) 473
TABLE 663 CHINA: BIOMARKERS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 474
TABLE 664 CHINA: BIOMARKERS MARKET, BY END USER, 2024–2031 (USD MILLION) 474
TABLE 665 JAPAN: BIOMARKERS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 475
TABLE 666 JAPAN: BIOMARKER CONSUMABLES MARKET, BY TYPE,
2024–2031 (USD MILLION) 475
TABLE 667 JAPAN: BIOMARKERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 476
TABLE 668 JAPAN: EFFICACY BIOMARKERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 476
TABLE 669 JAPAN: BIOMARKERS MARKET, BY RESEARCH AREA, 2024–2031 (USD MILLION) 476
TABLE 670 JAPAN: BIOMARKERS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 477
TABLE 671 JAPAN: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE,
2024–2031 (USD MILLION) 477
TABLE 672 JAPAN: BIOMARKERS MARKET, BY DISEASE INDICATION,
2024–2031 (USD MILLION) 478
TABLE 673 JAPAN: BIOMARKERS MARKET FOR CANCER, BY TYPE, 2024–2031 (USD MILLION) 478
TABLE 674 JAPAN: BIOMARKERS MARKET FOR INFECTIOUS DISEASES, BY TYPE,
2024–2031 (USD MILLION) 479
TABLE 675 JAPAN: BIOMARKERS MARKET FOR IMMUNOLOGICAL DISORDERS, BY TYPE, 2024–2031 (USD MILLION) 479
TABLE 676 JAPAN: BIOMARKERS MARKET FOR NEUROLOGICAL DISORDERS, BY TYPE,
2024–2031 (USD MILLION) 480
TABLE 677 JAPAN: BIOMARKERS MARKET FOR METABOLIC & ENDOCRINE DISORDERS,
BY TYPE, 2024–2031 (USD MILLION) 480
TABLE 678 JAPAN: BIOMARKERS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 481
TABLE 679 JAPAN: BIOMARKERS MARKET, BY END USER, 2024–2031 (USD MILLION) 481
TABLE 680 INDIA: BIOMARKERS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 482
TABLE 681 INDIA: BIOMARKER CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION) 482
TABLE 682 INDIA: BIOMARKERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 483
TABLE 683 INDIA: EFFICACY BIOMARKERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 483
TABLE 684 INDIA: BIOMARKERS MARKET, BY RESEARCH AREA, 2024–2031 (USD MILLION) 483
TABLE 685 INDIA: BIOMARKERS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 484
TABLE 686 INDIA: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE,
2024–2031 (USD MILLION) 484
TABLE 687 INDIA: BIOMARKERS MARKET, BY DISEASE INDICATION,
2024–2031 (USD MILLION) 485
TABLE 688 INDIA: BIOMARKERS MARKET FOR CANCER, BY TYPE, 2024–2031 (USD MILLION) 485
TABLE 689 INDIA: BIOMARKERS MARKET FOR INFECTIOUS DISEASES, BY TYPE,
2024–2031 (USD MILLION) 486
TABLE 690 INDIA: BIOMARKERS MARKET FOR IMMUNOLOGICAL DISORDERS,
BY TYPE, 2024–2031 (USD MILLION) 486
TABLE 691 INDIA: BIOMARKERS MARKET FOR NEUROLOGICAL DISORDERS,
BY TYPE, 2024–2031 (USD MILLION) 487
TABLE 692 INDIA: BIOMARKERS MARKET FOR METABOLIC & ENDOCRINE DISORDERS,
BY TYPE, 2024–2031 (USD MILLION) 487
TABLE 693 INDIA: BIOMARKERS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 488
TABLE 694 INDIA: BIOMARKERS MARKET, BY END USER, 2024–2031 (USD MILLION) 488
TABLE 695 SOUTH KOREA: BIOMARKERS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 489
TABLE 696 SOUTH KOREA: BIOMARKER CONSUMABLES MARKET, BY TYPE,
2024–2031 (USD MILLION) 489
TABLE 697 SOUTH KOREA: BIOMARKERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 490
TABLE 698 SOUTH KOREA: EFFICACY BIOMARKERS MARKET, BY TYPE,
2024–2031 (USD MILLION) 490
TABLE 699 SOUTH KOREA: BIOMARKERS MARKET, BY RESEARCH AREA,
2024–2031 (USD MILLION) 490
TABLE 700 SOUTH KOREA: BIOMARKERS MARKET, BY TECHNOLOGY,
2024–2031 (USD MILLION) 491
TABLE 701 SOUTH KOREA: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE,
2024–2031 (USD MILLION) 491
TABLE 702 SOUTH KOREA: BIOMARKERS MARKET, BY DISEASE INDICATION,
2024–2031 (USD MILLION) 492
TABLE 703 SOUTH KOREA: BIOMARKERS MARKET FOR CANCER, BY TYPE,
2024–2031 (USD MILLION) 492
TABLE 704 SOUTH KOREA: BIOMARKERS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2024–2031 (USD MILLION) 493
TABLE 705 SOUTH KOREA: BIOMARKERS MARKET FOR IMMUNOLOGICAL DISORDERS,
BY TYPE, 2024–2031 (USD MILLION) 493
TABLE 706 SOUTH KOREA: BIOMARKERS MARKET FOR NEUROLOGICAL DISORDERS,
BY TYPE, 2024–2031 (USD MILLION) 494
TABLE 707 SOUTH KOREA: BIOMARKERS MARKET FOR METABOLIC & ENDOCRINE DISORDERS, BY TYPE, 2024–2031 (USD MILLION) 494
TABLE 708 SOUTH KOREA: BIOMARKERS MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 495
TABLE 709 SOUTH KOREA: BIOMARKERS MARKET, BY END USER, 2024–2031 (USD MILLION) 495
TABLE 710 AUSTRALIA: BIOMARKERS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 496
TABLE 711 AUSTRALIA: BIOMARKER CONSUMABLES MARKET, BY TYPE,
2024–2031 (USD MILLION) 496
TABLE 712 AUSTRALIA: BIOMARKERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 496
TABLE 713 AUSTRALIA: EFFICACY BIOMARKERS MARKET, BY TYPE,
2024–2031 (USD MILLION) 497
TABLE 714 AUSTRALIA: BIOMARKERS MARKET, BY RESEARCH AREA, 2024–2031 (USD MILLION) 497
TABLE 715 AUSTRALIA: BIOMARKERS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 498
TABLE 716 AUSTRALIA: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE,
2024–2031 (USD MILLION) 498
TABLE 717 AUSTRALIA: BIOMARKERS MARKET, BY DISEASE INDICATION,
2024–2031 (USD MILLION) 499
TABLE 718 AUSTRALIA: BIOMARKERS MARKET FOR CANCER, BY TYPE,
2024–2031 (USD MILLION) 499
TABLE 719 AUSTRALIA: BIOMARKERS MARKET FOR INFECTIOUS DISEASES, BY TYPE,
2024–2031 (USD MILLION) 500
TABLE 720 AUSTRALIA: BIOMARKERS MARKET FOR IMMUNOLOGICAL DISORDERS, BY TYPE, 2024–2031 (USD MILLION) 500
TABLE 721 AUSTRALIA: BIOMARKERS MARKET FOR NEUROLOGICAL DISORDERS, BY TYPE, 2024–2031 (USD MILLION) 500
TABLE 722 AUSTRALIA: BIOMARKERS MARKET FOR METABOLIC & ENDOCRINE DISORDERS, BY TYPE, 2024–2031 (USD MILLION) 501
TABLE 723 AUSTRALIA: BIOMARKERS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 501
TABLE 724 AUSTRALIA: BIOMARKERS MARKET, BY END USER, 2024–2031 (USD MILLION) 502
TABLE 725 REST OF ASIA PACIFIC: BIOMARKERS MARKET, BY OFFERING,
2024–2031 (USD MILLION) 503
TABLE 726 REST OF ASIA PACIFIC: BIOMARKER CONSUMABLES MARKET, BY TYPE,
2024–2031 (USD MILLION) 503
TABLE 727 REST OF ASIA PACIFIC: BIOMARKERS MARKET, BY TYPE,
2024–2031 (USD MILLION) 503
TABLE 728 REST OF ASIA PACIFIC: EFFICACY BIOMARKERS MARKET, BY TYPE,
2024–2031 (USD MILLION) 504
TABLE 729 REST OF ASIA PACIFIC: BIOMARKERS MARKET, BY RESEARCH AREA,
2024–2031 (USD MILLION) 504
TABLE 730 REST OF ASIA PACIFIC: BIOMARKERS MARKET, BY TECHNOLOGY,
2024–2031 (USD MILLION) 505
TABLE 731 REST OF ASIA PACIFIC: BIOMARKERS MARKET FOR IMMUNOASSAYS,
BY TYPE, 2024–2031 (USD MILLION) 505
TABLE 732 REST OF ASIA PACIFIC: BIOMARKERS MARKET, BY DISEASE INDICATION,
2024–2031 (USD MILLION) 506
TABLE 733 REST OF ASIA PACIFIC: BIOMARKERS MARKET FOR CANCER, BY TYPE,
2024–2031 (USD MILLION) 506
TABLE 734 REST OF ASIA PACIFIC: BIOMARKERS MARKET FOR INFECTIOUS DISEASES,
BY TYPE, 2024–2031 (USD MILLION) 507
TABLE 735 REST OF ASIA PACIFIC: BIOMARKERS MARKET FOR IMMUNOLOGICAL DISORDERS, BY TYPE, 2024–2031 (USD MILLION) 507
TABLE 736 REST OF ASIA PACIFIC: BIOMARKERS MARKET FOR NEUROLOGICAL DISORDERS, BY TYPE, 2024–2031 (USD MILLION) 508
TABLE 737 REST OF ASIA PACIFIC: BIOMARKERS MARKET FOR METABOLIC & ENDOCRINE DISORDERS, BY TYPE, 2024–2031 (USD MILLION) 508
TABLE 738 REST OF ASIA PACIFIC: BIOMARKERS MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 509
TABLE 739 REST OF ASIA PACIFIC: BIOMARKERS MARKET, BY END USER,
2024–2031 (USD MILLION) 509
TABLE 740 LATIN AMERICA: BIOMARKERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 510
TABLE 741 LATIN AMERICA: BIOMARKERS MARKET, BY OFFERING,
2024–2031 (USD MILLION) 510
TABLE 742 LATIN AMERICA: BIOMARKER CONSUMABLES MARKET, BY TYPE,
2024–2031 (USD MILLION) 510
TABLE 743 LATIN AMERICA: BIOMARKERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 511
TABLE 744 LATIN AMERICA: EFFICACY BIOMARKERS MARKET, BY TYPE,
2024–2031 (USD MILLION) 511
TABLE 745 LATIN AMERICA: BIOMARKERS MARKET, BY RESEARCH AREA,
2024–2031 (USD MILLION) 512
TABLE 746 LATIN AMERICA: BIOMARKERS MARKET, BY TECHNOLOGY,
2024–2031 (USD MILLION) 512
TABLE 747 LATIN AMERICA: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE,
2024–2031 (USD MILLION) 513
TABLE 748 LATIN AMERICA: BIOMARKERS MARKET, BY DISEASE INDICATION,
2024–2031 (USD MILLION) 513
TABLE 749 LATIN AMERICA: BIOMARKERS MARKET FOR CANCER, BY TYPE,
2024–2031 (USD MILLION) 514
TABLE 750 LATIN AMERICA: BIOMARKERS MARKET FOR INFECTIOUS DISEASES,
BY TYPE, 2024–2031 (USD MILLION) 514
TABLE 751 LATIN AMERICA: BIOMARKERS MARKET FOR IMMUNOLOGICAL DISORDERS,
BY TYPE, 2024–2031 (USD MILLION) 515
TABLE 752 LATIN AMERICA: BIOMARKERS MARKET FOR NEUROLOGICAL DISORDERS,
BY TYPE, 2024–2031 (USD MILLION) 515
TABLE 753 LATIN AMERICA: BIOMARKERS MARKET FOR METABOLIC & ENDOCRINE DISORDERS, BY TYPE, 2024–2031 (USD MILLION) 516
TABLE 754 LATIN AMERICA: BIOMARKERS MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 516
TABLE 755 LATIN AMERICA: BIOMARKERS MARKET, BY END USER,
2024–2031 (USD MILLION) 517
TABLE 756 BRAZIL: BIOMARKERS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 518
TABLE 757 BRAZIL: BIOMARKER CONSUMABLES MARKET, BY TYPE,
2024–2031 (USD MILLION) 518
TABLE 758 BRAZIL: BIOMARKERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 518
TABLE 759 BRAZIL: EFFICACY BIOMARKERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 519
TABLE 760 BRAZIL: BIOMARKERS MARKET, BY RESEARCH AREA, 2024–2031 (USD MILLION) 519
TABLE 761 BRAZIL: BIOMARKERS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 520
TABLE 762 BRAZIL: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE,
2024–2031 (USD MILLION) 520
TABLE 763 BRAZIL: BIOMARKERS MARKET, BY DISEASE INDICATION,
2024–2031 (USD MILLION) 521
TABLE 764 BRAZIL: BIOMARKERS MARKET FOR CANCER, BY TYPE,
2024–2031 (USD MILLION) 521
TABLE 765 BRAZIL: BIOMARKERS MARKET FOR INFECTIOUS DISEASES, BY TYPE,
2024–2031 (USD MILLION) 522
TABLE 766 BRAZIL: BIOMARKERS MARKET FOR IMMUNOLOGICAL DISORDERS,
BY TYPE, 2024–2031 (USD MILLION) 522
TABLE 767 BRAZIL: BIOMARKERS MARKET FOR NEUROLOGICAL DISORDERS,
BY TYPE, 2024–2031 (USD MILLION) 523
TABLE 768 BRAZIL: BIOMARKERS MARKET FOR METABOLIC & ENDOCRINE DISORDERS,
BY TYPE, 2024–2031 (USD MILLION) 523
TABLE 769 BRAZIL: BIOMARKERS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 524
TABLE 770 BRAZIL: BIOMARKERS MARKET, BY END USER, 2024–2031 (USD MILLION) 524
TABLE 771 MEXICO: BIOMARKERS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 525
TABLE 772 MEXICO: BIOMARKER CONSUMABLES MARKET, BY TYPE,
2024–2031 (USD MILLION) 525
TABLE 773 MEXICO: BIOMARKERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 526
TABLE 774 MEXICO: EFFICACY BIOMARKERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 526
TABLE 775 MEXICO: BIOMARKERS MARKET, BY RESEARCH AREA, 2024–2031 (USD MILLION) 526
TABLE 776 MEXICO: BIOMARKERS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 527
TABLE 777 MEXICO: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE,
2024–2031 (USD MILLION) 527
TABLE 778 MEXICO: BIOMARKERS MARKET, BY DISEASE INDICATION,
2024–2031 (USD MILLION) 528
TABLE 779 MEXICO: BIOMARKERS MARKET FOR CANCER, BY TYPE,
2024–2031 (USD MILLION) 528
TABLE 780 MEXICO: BIOMARKERS MARKET FOR INFECTIOUS DISEASES, BY TYPE,
2024–2031 (USD MILLION) 529
TABLE 781 MEXICO: BIOMARKERS MARKET FOR IMMUNOLOGICAL DISORDERS, BY TYPE, 2024–2031 (USD MILLION) 529
TABLE 782 MEXICO: BIOMARKERS MARKET FOR NEUROLOGICAL DISORDERS, BY TYPE, 2024–2031 (USD MILLION) 530
TABLE 783 MEXICO: BIOMARKERS MARKET FOR METABOLIC & ENDOCRINE DISORDERS,
BY TYPE, 2024–2031 (USD MILLION) 530
TABLE 784 MEXICO: BIOMARKERS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 531
TABLE 785 MEXICO: BIOMARKERS MARKET, BY END USER, 2024–2031 (USD MILLION) 531
TABLE 786 REST OF LATIN AMERICA: BIOMARKERS MARKET, BY OFFERING,
2024–2031 (USD MILLION) 532
TABLE 787 REST OF LATIN AMERICA: BIOMARKER CONSUMABLES MARKET, BY TYPE,
2024–2031 (USD MILLION) 532
TABLE 788 REST OF LATIN AMERICA: BIOMARKERS MARKET, BY TYPE,
2024–2031 (USD MILLION) 533
TABLE 789 REST OF LATIN AMERICA: EFFICACY BIOMARKERS MARKET, BY TYPE,
2024–2031 (USD MILLION) 533
TABLE 790 REST OF LATIN AMERICA: BIOMARKERS MARKET, BY RESEARCH AREA,
2024–2031 (USD MILLION) 533
TABLE 791 REST OF LATIN AMERICA: BIOMARKERS MARKET, BY TECHNOLOGY,
2024–2031 (USD MILLION) 534
TABLE 792 REST OF LATIN AMERICA: BIOMARKERS MARKET FOR IMMUNOASSAYS,
BY TYPE, 2024–2031 (USD MILLION) 534
TABLE 793 REST OF LATIN AMERICA: BIOMARKERS MARKET, BY DISEASE INDICATION,
2024–2031 (USD MILLION) 535
TABLE 794 REST OF LATIN AMERICA: BIOMARKERS MARKET FOR CANCER, BY TYPE,
2024–2031 (USD MILLION) 535
TABLE 795 REST OF LATIN AMERICA: BIOMARKERS MARKET FOR INFECTIOUS DISEASES,
BY TYPE, 2024–2031 (USD MILLION) 536
TABLE 796 REST OF LATIN AMERICA: BIOMARKERS MARKET FOR IMMUNOLOGICAL DISORDERS, BY TYPE, 2024–2031 (USD MILLION) 536
TABLE 797 REST OF LATIN AMERICA: BIOMARKERS MARKET FOR NEUROLOGICAL DISORDERS, BY TYPE, 2024–2031 (USD MILLION) 537
TABLE 798 REST OF LATIN AMERICA: BIOMARKERS MARKET FOR METABOLIC & ENDOCRINE DISORDERS, BY TYPE, 2024–2031 (USD MILLION) 537
TABLE 799 REST OF LATIN AMERICA: BIOMARKERS MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 538
TABLE 800 REST OF LATIN AMERICA: BIOMARKERS MARKET, BY END USER,
2024–2031 (USD MILLION) 538
TABLE 801 MIDDLE EAST: BIOMARKERS MARKET, BY REGION, 2024–2031 (USD MILLION) 539
TABLE 802 MIDDLE EAST: BIOMARKERS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 539
TABLE 803 MIDDLE EAST: BIOMARKER CONSUMABLES MARKET, BY TYPE,
2024–2031 (USD MILLION) 539
TABLE 804 MIDDLE EAST: BIOMARKERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 540
TABLE 805 MIDDLE EAST: EFFICACY BIOMARKERS MARKET, BY TYPE,
2024–2031 (USD MILLION) 540
TABLE 806 MIDDLE EAST: BIOMARKERS MARKET, BY RESEARCH AREA,
2024–2031 (USD MILLION) 540
TABLE 807 MIDDLE EAST: BIOMARKERS MARKET, BY TECHNOLOGY,
2024–2031 (USD MILLION) 541
TABLE 808 MIDDLE EAST: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE,
2024–2031 (USD MILLION) 541
TABLE 809 MIDDLE EAST: BIOMARKERS MARKET, BY DISEASE INDICATION,
2024–2031 (USD MILLION) 542
TABLE 810 MIDDLE EAST: BIOMARKERS MARKET FOR CANCER, BY TYPE,
2024–2031 (USD MILLION) 542
TABLE 811 MIDDLE EAST: BIOMARKERS MARKET FOR INFECTIOUS DISEASES,
BY TYPE, 2024–2031 (USD MILLION) 543
TABLE 812 MIDDLE EAST: BIOMARKERS MARKET FOR IMMUNOLOGICAL DISORDERS,
BY TYPE, 2024–2031 (USD MILLION) 543
TABLE 813 MIDDLE EAST: BIOMARKERS MARKET FOR NEUROLOGICAL DISORDERS,
BY TYPE, 2024–2031 (USD MILLION) 544
TABLE 814 MIDDLE EAST: BIOMARKERS MARKET FOR METABOLIC & ENDOCRINE DISORDERS, BY TYPE, 2024–2031 (USD MILLION) 544
TABLE 815 MIDDLE EAST: BIOMARKERS MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 545
TABLE 816 MIDDLE EAST: BIOMARKERS MARKET, BY END USER, 2024–2031 (USD MILLION) 545
TABLE 817 GCC COUNTRIES: BIOMARKERS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 546
TABLE 818 GCC COUNTRIES: BIOMARKERS MARKET, BY OFFERING,
2024–2031 (USD MILLION) 546
TABLE 819 GCC COUNTRIES: BIOMARKER CONSUMABLES MARKET, BY TYPE,
2024–2031 (USD MILLION) 547
TABLE 820 GCC COUNTRIES: BIOMARKERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 547
TABLE 821 GCC COUNTRIES: EFFICACY BIOMARKERS MARKET, BY TYPE,
2024–2031 (USD MILLION) 547
TABLE 822 GCC COUNTRIES: BIOMARKERS MARKET, BY RESEARCH AREA,
2024–2031 (USD MILLION) 548
TABLE 823 GCC COUNTRIES: BIOMARKERS MARKET, BY TECHNOLOGY,
2024–2031 (USD MILLION) 548
TABLE 824 GCC COUNTRIES: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE,
2024–2031 (USD MILLION) 549
TABLE 825 GCC COUNTRIES: BIOMARKERS MARKET, BY DISEASE INDICATION,
2024–2031 (USD MILLION) 549
TABLE 826 GCC COUNTRIES: BIOMARKERS MARKET FOR CANCER, BY TYPE,
2024–2031 (USD MILLION) 550
TABLE 827 GCC COUNTRIES: BIOMARKERS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2024–2031 (USD MILLION) 550
TABLE 828 GCC COUNTRIES: BIOMARKERS MARKET FOR IMMUNOLOGICAL DISORDERS,
BY TYPE, 2024–2031 (USD MILLION) 551
TABLE 829 GCC COUNTRIES: BIOMARKERS MARKET FOR NEUROLOGICAL DISORDERS,
BY TYPE, 2024–2031 (USD MILLION) 551
TABLE 830 GCC COUNTRIES: BIOMARKERS MARKET FOR METABOLIC & ENDOCRINE DISORDERS, BY TYPE, 2024–2031 (USD MILLION) 552
TABLE 831 GCC COUNTRIES: BIOMARKERS MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 552
TABLE 832 GCC COUNTRIES: BIOMARKERS MARKET, BY END USER,
2024–2031 (USD MILLION) 553
TABLE 833 SAUDI ARABIA: BIOMARKERS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 554
TABLE 834 SAUDI ARABIA: BIOMARKER CONSUMABLES MARKET, BY TYPE,
2024–2031 (USD MILLION) 554
TABLE 835 SAUDI ARABIA: BIOMARKERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 554
TABLE 836 SAUDI ARABIA: EFFICACY BIOMARKERS MARKET, BY TYPE,
2024–2031 (USD MILLION) 555
TABLE 837 SAUDI ARABIA: BIOMARKERS MARKET, BY RESEARCH AREA,
2024–2031 (USD MILLION) 555
TABLE 838 SAUDI ARABIA: BIOMARKERS MARKET, BY TECHNOLOGY,
2024–2031 (USD MILLION) 556
TABLE 839 SAUDI ARABIA: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE,
2024–2031 (USD MILLION) 556
TABLE 840 SAUDI ARABIA: BIOMARKERS MARKET, BY DISEASE INDICATION,
2024–2031 (USD MILLION) 557
TABLE 841 SAUDI ARABIA: BIOMARKERS MARKET FOR CANCER, BY TYPE,
2024–2031 (USD MILLION) 557
TABLE 842 SAUDI ARABIA: BIOMARKERS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2024–2031 (USD MILLION) 558
TABLE 843 SAUDI ARABIA: BIOMARKERS MARKET FOR IMMUNOLOGICAL DISORDERS,
BY TYPE, 2024–2031 (USD MILLION) 558
TABLE 844 SAUDI ARABIA: BIOMARKERS MARKET FOR NEUROLOGICAL DISORDERS,
BY TYPE, 2024–2031 (USD MILLION) 559
TABLE 845 SAUDI ARABIA: BIOMARKERS MARKET FOR METABOLIC & ENDOCRINE DISORDERS, BY TYPE, 2024–2031 (USD MILLION) 559
TABLE 846 SAUDI ARABIA: BIOMARKERS MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 560
TABLE 847 SAUDI ARABIA: BIOMARKERS MARKET, BY END USER, 2024–2031 (USD MILLION) 560
TABLE 848 UAE: BIOMARKERS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 561
TABLE 849 UAE: BIOMARKER CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION) 561
TABLE 850 UAE: BIOMARKERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 562
TABLE 851 UAE: EFFICACY BIOMARKERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 562
TABLE 852 UAE: BIOMARKERS MARKET, BY RESEARCH AREA, 2024–2031 (USD MILLION) 562
TABLE 853 UAE: BIOMARKERS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 563
TABLE 854 UAE: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE,
2024–2031 (USD MILLION) 563
TABLE 855 UAE: BIOMARKERS MARKET, BY DISEASE INDICATION, 2024–2031 (USD MILLION) 564
TABLE 856 UAE: BIOMARKERS MARKET FOR CANCER, BY TYPE, 2024–2031 (USD MILLION) 564
TABLE 857 UAE: BIOMARKERS MARKET FOR INFECTIOUS DISEASES, BY TYPE,
2024–2031 (USD MILLION) 565
TABLE 858 UAE: BIOMARKERS MARKET FOR IMMUNOLOGICAL DISORDERS, BY TYPE,
2024–2031 (USD MILLION) 565
TABLE 859 UAE: BIOMARKERS MARKET FOR NEUROLOGICAL DISORDERS, BY TYPE,
2024–2031 (USD MILLION) 565
TABLE 860 UAE: BIOMARKERS MARKET FOR METABOLIC & ENDOCRINE DISORDERS, BY TYPE, 2024–2031 (USD MILLION) 566
TABLE 861 UAE: BIOMARKERS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 566
TABLE 862 UAE: BIOMARKERS MARKET, BY END USER, 2024–2031 (USD MILLION) 567
TABLE 863 REST OF GCC COUNTRIES: BIOMARKERS MARKET, BY OFFERING,
2024–2031 (USD MILLION) 568
TABLE 864 REST OF GCC COUNTRIES: BIOMARKER CONSUMABLES MARKET, BY TYPE,
2024–2031 (USD MILLION) 568
TABLE 865 REST OF GCC COUNTRIES: BIOMARKERS MARKET, BY TYPE,
2024–2031 (USD MILLION) 568
TABLE 866 REST OF GCC COUNTRIES: EFFICACY BIOMARKERS MARKET, BY TYPE,
2024–2031 (USD MILLION) 569
TABLE 867 REST OF GCC COUNTRIES: BIOMARKERS MARKET, BY RESEARCH AREA,
2024–2031 (USD MILLION) 569
TABLE 868 REST OF GCC COUNTRIES: BIOMARKERS MARKET, BY TECHNOLOGY,
2024–2031 (USD MILLION) 570
TABLE 869 REST OF GCC COUNTRIES: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE, 2024–2031 (USD MILLION) 570
TABLE 870 REST OF GCC COUNTRIES: BIOMARKERS MARKET, BY DISEASE INDICATION, 2024–2031 (USD MILLION) 571
TABLE 871 REST OF GCC COUNTRIES: BIOMARKERS MARKET FOR CANCER, BY TYPE,
2024–2031 (USD MILLION) 571
TABLE 872 REST OF GCC COUNTRIES: BIOMARKERS MARKET FOR INFECTIOUS DISEASES,
BY TYPE, 2024–2031 (USD MILLION) 572
TABLE 873 REST OF GCC COUNTRIES: BIOMARKERS MARKET FOR IMMUNOLOGICAL DISORDERS, BY TYPE, 2024–2031 (USD MILLION) 572
TABLE 874 REST OF GCC COUNTRIES: BIOMARKERS MARKET FOR NEUROLOGICAL DISORDERS, BY TYPE, 2024–2031 (USD MILLION) 572
TABLE 875 REST OF GCC COUNTRIES: BIOMARKERS MARKET FOR METABOLIC & ENDOCRINE DISORDERS, BY TYPE, 2024–2031 (USD MILLION) 573
TABLE 876 REST OF GCC COUNTRIES: BIOMARKERS MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 573
TABLE 877 REST OF GCC COUNTRIES: BIOMARKERS MARKET, BY END USER,
2024–2031 (USD MILLION) 574
TABLE 878 REST OF MIDDLE EAST: BIOMARKERS MARKET, BY OFFERING,
2024–2031 (USD MILLION) 575
TABLE 879 REST OF MIDDLE EAST: BIOMARKER CONSUMABLES MARKET, BY TYPE,
2024–2031 (USD MILLION) 575
TABLE 880 REST OF MIDDLE EAST: BIOMARKERS MARKET, BY TYPE,
2024–2031 (USD MILLION) 575
TABLE 881 REST OF MIDDLE EAST: EFFICACY BIOMARKERS MARKET, BY TYPE,
2024–2031 (USD MILLION) 576
TABLE 882 REST OF MIDDLE EAST: BIOMARKERS MARKET, BY RESEARCH AREA,
2024–2031 (USD MILLION) 576
TABLE 883 REST OF MIDDLE EAST: BIOMARKERS MARKET, BY TECHNOLOGY,
2024–2031 (USD MILLION) 577
TABLE 884 REST OF MIDDLE EAST: BIOMARKERS MARKET FOR IMMUNOASSAYS,
BY TYPE, 2024–2031 (USD MILLION) 577
TABLE 885 REST OF MIDDLE EAST: BIOMARKERS MARKET, BY DISEASE INDICATION,
2024–2031 (USD MILLION) 578
TABLE 886 REST OF MIDDLE EAST: BIOMARKERS MARKET FOR CANCER, BY TYPE,
2024–2031 (USD MILLION) 578
TABLE 887 REST OF MIDDLE EAST: BIOMARKERS MARKET FOR INFECTIOUS DISEASES,
BY TYPE, 2024–2031 (USD MILLION) 579
TABLE 888 REST OF MIDDLE EAST: BIOMARKERS MARKET FOR IMMUNOLOGICAL DISORDERS, BY TYPE, 2024–2031 (USD MILLION) 579
TABLE 889 REST OF MIDDLE EAST: BIOMARKERS MARKET FOR NEUROLOGICAL DISORDERS, BY TYPE, 2024–2031 (USD MILLION) 579
TABLE 890 REST OF MIDDLE EAST: BIOMARKERS MARKET FOR METABOLIC & ENDOCRINE DISORDERS, BY TYPE, 2024–2031 (USD MILLION) 580
TABLE 891 REST OF MIDDLE EAST: BIOMARKERS MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 580
TABLE 892 REST OF MIDDLE EAST: BIOMARKERS MARKET, BY END USER,
2024–2031 (USD MILLION) 581
TABLE 893 AFRICA: BIOMARKERS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 581
TABLE 894 AFRICA: BIOMARKER CONSUMABLES MARKET, BY TYPE,
2024–2031 (USD MILLION) 582
TABLE 895 AFRICA: BIOMARKERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 582
TABLE 896 AFRICA: EFFICACY BIOMARKERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 582
TABLE 897 AFRICA: BIOMARKERS MARKET, BY RESEARCH AREA, 2024–2031 (USD MILLION) 583
TABLE 898 AFRICA: BIOMARKERS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 583
TABLE 899 AFRICA: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE,
2024–2031 (USD MILLION) 584
TABLE 900 AFRICA: BIOMARKERS MARKET, BY DISEASE INDICATION,
2024–2031 (USD MILLION) 584
TABLE 901 AFRICA: BIOMARKERS MARKET FOR CANCER, BY TYPE,
2024–2031 (USD MILLION) 585
TABLE 902 AFRICA: BIOMARKERS MARKET FOR INFECTIOUS DISEASES, BY TYPE,
2024–2031 (USD MILLION) 585
TABLE 903 AFRICA: BIOMARKERS MARKET FOR IMMUNOLOGICAL DISORDERS, BY TYPE, 2024–2031 (USD MILLION) 586
TABLE 904 AFRICA: BIOMARKERS MARKET FOR NEUROLOGICAL DISORDERS, BY TYPE,
2024–2031 (USD MILLION) 586
TABLE 905 AFRICA: BIOMARKERS MARKET FOR METABOLIC & ENDOCRINE DISORDERS,
BY TYPE, 2024–2031 (USD MILLION) 587
TABLE 906 AFRICA: BIOMARKERS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 587
TABLE 907 AFRICA: BIOMARKERS MARKET, BY END USER, 2024–2031 (USD MILLION) 588
TABLE 908 OVERVIEW OF STRATEGIES DEPLOYED BY KEY PLAYERS IN BIOMARKERS MARKET 589
TABLE 909 BIOMARKERS MARKET: DEGREE OF COMPETITION 592
TABLE 910 BIOMARKERS MARKET: REGION FOOTPRINT 597
TABLE 911 BIOMARKERS MARKET: OFFERING FOOTPRINT 598
TABLE 912 BIOMARKERS MARKET: TECHNOLOGY FOOTPRINT 599
TABLE 913 BIOMARKERS MARKET: APPLICATION FOOTPRINT 601
TABLE 914 BIOMARKERS MARKET: DETAILED LIST OF KEY STARTUPS/SME PLAYERS 604
TABLE 915 BIOMARKERS MARKET: COMPETITIVE BENCHMARKING OF
KEY STARTUPS/SMES PLAYERS 605
TABLE 916 BIOMARKERS MARKET: PRODUCT LAUNCHES & APPROVALS,
JANUARY 2023–JUNE 2026 608
TABLE 917 BIOMARKERS MARKET: DEALS, JANUARY 2023–JUNE 2026 609
TABLE 918 BIOMARKERS MARKET: EXPANSIONS, JANUARY 2023–JUNE 2026 610
TABLE 919 F. HOFFMANN-LA ROCHE LTD.: BUSINESS OVERVIEW 611
TABLE 920 F. HOFFMANN-LA ROCHE LTD.: PRODUCTS & SERVICES OFFERED 612
TABLE 921 F. HOFFMANN-LA ROCHE LTD.: PRODUCT LAUNCHES & APPROVALS,
JANUARY 2023–JUNE 2026 615
TABLE 922 F. HOFFMANN-LA ROCHE LTD.: DEALS, JANUARY 2023–JUNE 2026 617
TABLE 923 DANAHER CORPORATION: COMPANY OVERVIEW 619
TABLE 924 DANAHER CORPORATION: PRODUCTS OFFERED 620
TABLE 925 ILLUMINA, INC.: BUSINESS OVERVIEW 623
TABLE 926 ILLUMINA, INC.: PRODUCTS & SERVICES OFFERED 624
TABLE 927 ILLUMINA, INC.: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023–JUNE 2026 625
TABLE 928 ILLUMINA, INC.: DEALS, JANUARY 2023—JUNE 2026 625
TABLE 929 MERCK KGAA: BUSINESS OVERVIEW 627
TABLE 930 MERCK KGAA: PRODUCTS & SERVICES OFFERED 628
TABLE 931 MERCK KGAA: DEALS, JANUARY 2023–JUNE 2026 632
TABLE 932 MERCK KGAA: EXPANSIONS, JANUARY 2023–JUNE 2026 633
TABLE 933 THERMO FISHER SCIENTIFIC INC.: BUSINESS OVERVIEW 634
TABLE 934 THERMO FISHER SCIENTIFIC INC.: PRODUCTS & SERVICES OFFERED 635
TABLE 935 THERMO FISHER SCIENTIFIC INC.: PRODUCT APPROVALS,
JANUARY 2023–JUNE 2026 641
TABLE 936 THERMO FISHER SCIENTIFIC INC.: DEALS, JANUARY 2023–JUNE 2026 641
TABLE 937 THERMO FISHER SCIENTIFIC INC.: EXPANSIONS, JANUARY 2023–JUNE 2026 643
TABLE 938 QIAGEN: BUSINESS OVERVIEW 645
TABLE 939 QIAGEN: PRODUCTS & SERVICES OFFERED 646
TABLE 940 QIAGEN: PRODUCT LAUNCHES, JANUARY 2023–JUNE 2026 649
TABLE 941 QIAGEN: DEALS, JANUARY 2023–JUNE 2026 649
TABLE 942 QIAGEN: EXPANSIONS, JANUARY 2023–JUNE 2026 650
TABLE 943 ABBOTT: BUSINESS OVERVIEW 651
TABLE 944 ABBOTT: PRODUCTS & SERVICES OFFERED 652
TABLE 945 ABBOTT: PRODUCT APPROVALS, JANUARY 2023—JUNE 2026 654
TABLE 946 ABBOTT: DEALS, JANUARY 2023—JUNE 2026 654
TABLE 947 AGILENT TECHNOLOGIES, INC.: BUSINESS OVERVIEW 655
TABLE 948 AGILENT TECHNOLOGIES, INC.: PRODUCTS & SERVICES OFFERED 656
TABLE 949 AGILENT TECHNOLOGIES, INC.: PRODUCT APPROVALS, JANUARY 2023—JUNE 2026 657
TABLE 950 AGILENT TECHNOLOGIES, INC.: DEALS, JANUARY 2023—JUNE 2026 659
TABLE 951 REVVITY INC.: BUSINESS OVERVIEW 660
TABLE 952 REVVITY INC.: PRODUCTS & SERVICES OFFERED 661
TABLE 953 REVVITY INC.: PRODUCT LAUNCHES, JANUARY 2023—JUNE 2026 662
TABLE 954 CHARLES RIVER LABORATORIES: BUSINESS OVERVIEW 663
TABLE 955 CHARLES RIVER LABORATORIES: PRODUCTS & SERVICES OFFERED 664
TABLE 956 CHARLES RIVER LABORATORIES: DEALS, JANUARY 2023—JUNE 2026 665
TABLE 957 BIO-RAD LABORATORIES, INC.: BUSINESS OVERVIEW 666
TABLE 958 BIO-RAD LABORATORIES, INC.: PRODUCTS & SERVICES OFFERED 667
TABLE 959 BIO-RAD LABORATORIES, INC.: PRODUCT LAUNCHES, JANUARY 2023—JUNE 2026 668
TABLE 960 BIO-RAD LABORATORIES, INC.: DEALS, JANUARY 2023—JUNE 2026 669
TABLE 961 EUROFINS SCIENTIFIC: BUSINESS OVERVIEW 670
TABLE 962 EUROFINS SCIENTIFIC: PRODUCTS & SERVICES OFFERED 671
TABLE 963 EUROFINS SCIENTIFIC: DEALS, JANUARY 2023—JUNE 2026 672
TABLE 964 BIOMÉRIEUX: BUSINESS OVERVIEW 673
TABLE 965 BIOMÉRIEUX: PRODUCTS & SERVICES OFFERED 674
TABLE 966 BIOMÉRIEUX: PRODUCT APPROVALS, JANUARY 2023–JUNE 2026 675
TABLE 967 BIOMÉRIEUX: DEALS, JANUARY 2023—JUNE 2026 675
TABLE 968 BIOMÉRIEUX: EXPANSIONS, JANUARY 2023–JUNE 2026 676
TABLE 969 JSR CORPORATION: BUSINESS OVERVIEW 677
TABLE 970 JSR CORPORATION: PRODUCTS & SERVICES OFFERED 678
TABLE 971 JSR CORPORATION: DEALS, JANUARY 2023—JUNE 2026 679
TABLE 972 GUARDANT HEALTH: BUSINESS OVERVIEW 680
TABLE 973 GUARDANT HEALTH: PRODUCTS & SERVICES OFFERED 681
TABLE 974 GUARDANT HEALTH: PRODUCT APPROVALS, JANUARY 2023–JUNE 2026 682
TABLE 975 GUARDANT HEALTH: DEALS, JANUARY 2023—JUNE 2026 682
TABLE 976 LABCORP: BUSINESS OVERVIEW 685
TABLE 977 LABCORP: PRODUCTS & SERVICES OFFERED 686
TABLE 978 LABCORP: PRODUCT LAUNCHES, JANUARY 2023—JUNE 2026 687
TABLE 979 LABCORP: DEALS, JANUARY 2023—JUNE 2026 687
TABLE 980 QUANTERIX: BUSINESS OVERVIEW 688
TABLE 981 QUANTERIX: PRODUCTS & SERVICES OFFERED 689
TABLE 982 QUANTERIX: PRODUCT LAUNCHES, JANUARY 2023—JUNE 2026 690
TABLE 983 QUANTERIX: DEALS, JANUARY 2023—JUNE 2026 690
TABLE 984 MESO SCALE DIAGNOSTICS, LLC: BUSINESS OVERVIEW 691
TABLE 985 MESO SCALE DIAGNOSTICS, LLC: PRODUCTS & SERVICES OFFERED 691
TABLE 986 SIEMENS HEALTHINEERS AG: COMPANY OVERVIEW 693
TABLE 987 SIEMENS HEALTHINEERS AG: PRODUCTS OFFERED 694
TABLE 988 CELERION: COMPANY OVERVIEW 696
TABLE 989 STANDARD BIOTOOLS: COMPANY OVERVIEW 697
TABLE 990 SEBIA: COMPANY OVERVIEW 698
TABLE 991 BIOAGILYTIX LABS: COMPANY OVERVIEW 699
TABLE 992 STRESSMARQ BIOSCIENCES INC.: COMPANY OVERVIEW 700
TABLE 993 NORTHEAST BIOANALYTICAL LABORATORIES LLC: BUSINESS OVERVIEW 701
TABLE 994 SIGNOSIS: BUSINESS OVERVIEW 702
TABLE 995 SERIMMUNE: BUSINESS OVERVIEW 703
TABLE 996 THERAINDX LIFESCIENCES PVT. LTD.: BUSINESS OVERVIEW 703
TABLE 997 SYNEXA LIFE SCIENCES BV: BUSINESS OVERVIEW 704
TABLE 998 DIATECH PHARMACOGENETICS: BUSINESS OVERVIEW 705
TABLE 999 PILLAR BIOSCIENCES: BUSINESS OVERVIEW 706
TABLE 1000 R-BIOPHARM AG: BUSINESS OVERVIEW 707

LIST OF FIGURES

FIGURE 1 BIOMARKERS MARKET SEGMENTATION & REGIONAL SCOPE 57
FIGURE 2 BIOMARKERS MARKET: YEARS CONSIDERED 59
FIGURE 3 MARKET SCENARIO 62
FIGURE 4 GLOBAL BIOMARKERS MARKET, 2024–2031 62
FIGURE 5 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN BIOMARKERS MARKET,
2023–2026 63
FIGURE 6 DISRUPTIONS INFLUENCING GROWTH OF BIOMARKERS MARKET 64
FIGURE 7 HIGH-GROWTH SEGMENTS IN BIOMARKERS MARKET, 2026–2031 65
FIGURE 8 ASIA PACIFIC TO REGISTER HIGHEST CAGR IN BIOMARKERS MARKET, IN TERMS OF VALUE, DURING FORECAST PERIOD 66
FIGURE 9 RISING ADOPTION OF PRECISION MEDICINE AND COMPANION DIAGNOSTICS TO DRIVE MARKET GROWTH 67
FIGURE 10 CONSUMABLES SEGMENT ACCOUNTED FOR LARGEST MARKET SHARE IN NORTH AMERICA IN 2025 68
FIGURE 11 CONSUMABLES TO DOMINATE MARKET DURING FORECAST PERIOD 69
FIGURE 12 CHINA TO REGISTER HIGHEST CAGR DURING FORECAST PERIOD 70
FIGURE 13 BIOMARKERS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 71
FIGURE 14 BIOMARKERS MARKET: PORTERS FIVE FORCES ANALYSIS 80
FIGURE 15 BIOMARKERS MARKET: SUPPLY CHAIN ANALYSIS 84
FIGURE 16 BIOMARKERS MARKET: VALUE CHAIN ANALYSIS 85
FIGURE 17 BIOMARKERS MARKET: ECOSYSTEM ANALYSIS 86
FIGURE 18 AVERAGE SELLING PRICE TREND OF ASSAY KITS, BY KEY PLAYER,
2023–2025 (USD) 89
FIGURE 19 INDICATIVE SELLING PRICE OF CONSUMABLES, BY REGION, 2025 90
FIGURE 20 BIOMARKERS MARKET: TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS 94
FIGURE 21 VC/PRIVATE EQUITY INVESTMENT TRENDS & STARTUP LANDSCAPE 95
FIGURE 22 TOP APPLICANTS/OWNERS (COMPANIES) FOR BIOMARKER PATENTS, 2015–2025 106
FIGURE 23 IMPACT OF AI/GEN AI ON BIOMARKERS MARKET 109
FIGURE 24 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY OFFERING 126
FIGURE 25 KEY BUYING CRITERIA, BY END USER 127
FIGURE 26 NORTH AMERICA: BIOMARKERS MARKET SNAPSHOT 383
FIGURE 27 ASIA PACIFIC: BIOMARKERS MARKET SNAPSHOT 459
FIGURE 28 REVENUE ANALYSIS OF KEY PLAYERS IN BIOMARKERS MARKET,
2023–2025 (USD MILLION) 591
FIGURE 29 MARKET SHARE ANALYSIS OF KEY PLAYERS IN BIOMARKERS MARKET (2025) 592
FIGURE 30 BIOMARKERS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2025 595
FIGURE 31 BIOMARKERS MARKET: COMPANY FOOTPRINT 596
FIGURE 32 BIOMARKERS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2025 603
FIGURE 33 EV/EBITDA OF KEY VENDORS 606
FIGURE 34 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA
OF KEY VENDORS 606
FIGURE 35 BIOMARKERS MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS 607
FIGURE 36 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2025) 612
FIGURE 37 DANAHER CORPORATION: COMPANY SNAPSHOT (2025) 620
FIGURE 38 ILLUMINA, INC.: COMPANY SNAPSHOT (2025) 624
FIGURE 39 MERCK KGAA: COMPANY SNAPSHOT (2025) 628
FIGURE 40 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2025) 635
FIGURE 41 QIAGEN: COMPANY SNAPSHOT (2025) 646
FIGURE 42 ABBOTT: COMPANY SNAPSHOT (2025) 652
FIGURE 43 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2025) 656
FIGURE 44 REVVITY INC.: COMPANY SNAPSHOT (2025) 661
FIGURE 45 CHARLES RIVER LABORATORIES: COMPANY SNAPSHOT (2025) 664
FIGURE 46 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2025) 667
FIGURE 47 EUROFINS SCIENTIFIC: COMPANY SNAPSHOT (2025) 671
FIGURE 48 BIOMÉRIEUX: COMPANY SNAPSHOT (2025) 674
FIGURE 49 JSR CORPORATION: COMPANY SNAPSHOT (2024) 678
FIGURE 50 GUARDANT HEALTH: COMPANY SNAPSHOT (2025) 681
FIGURE 51 LABCORP: COMPANY SNAPSHOT (2025) 686
FIGURE 52 QUANTERIX: COMPANY SNAPSHOT (2025) 688
FIGURE 53 SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT, 2025 694
FIGURE 54 RESEARCH DESIGN 708
FIGURE 55 BIOMARKERS MARKET: BREAKDOWN OF PRIMARY INTERVIEWS 710
FIGURE 56 BIOMARKERS MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2025 711
FIGURE 57 MARKET SIZE ESTIMATION: APPROACH 1 (COMPANY REVENUE
ANALYSIS-BASED ESTIMATION), 2025 712
FIGURE 58 ILLUSTRATIVE EXAMPLE OF HOFFMANN-LA ROCHE LTD.:
REVENUE SHARE ANALYSIS (2025) 713
FIGURE 59 MARKET SIZE VALIDATION FROM PRIMARY SOURCES 714
FIGURE 60 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH 715
FIGURE 61 BIOMARKERS MARKET (SUPPLY SIDE): CAGR PROJECTIONS 716
FIGURE 62 BIOMARKERS MARKET: GROWTH ANALYSIS OF MARKET DYNAMICS 717
FIGURE 63 DATA TRIANGULATION METHODOLOGY 718

---

---